Antisynthetase Syndrome

Complex MONDO:0019344 Pathograph 31 Show in embeddings browser Autoimmune Disease Inflammatory Myopathy

A systemic autoimmune disease and distinct subset of the idiopathic inflammatory myopathies, defined serologically by circulating autoantibodies against one of the cytoplasmic aminoacyl-tRNA synthetases (most commonly anti-Jo-1 / anti-histidyl-tRNA synthetase; also anti-PL-7, anti-PL-12, anti-EJ, anti-OJ, anti-KS). It is dominated by a constellation of interstitial lung disease (often the prognosis-determining feature), inflammatory myositis, and inflammatory (usually non-erosive) arthritis, frequently accompanied by mechanic's hands, Raynaud phenomenon, and unexplained fever. The ILD-predominant, antibody-defined phenotype distinguishes it from classic polymyositis and dermatomyositis. It is multifactorial/autoimmune (HLA-associated), not Mendelian.

Ask OpenScientist

Ask a research question about Antisynthetase Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
7
Pathophys.
13
Phenotypes
3
Gaps
31
Pathograph
8
Genes
8
Medical Actions
2
Differentials
1
Datasets
2
Trials
1
Models
15
References
1
Deep Research
🏷

Classifications

Harrison's Part
IMMUNE RHEUMATOLOGIC
👪

Inheritance

1
Not Mendelian (multifactorial autoimmune)
Antisynthetase syndrome is not inherited in a Mendelian fashion; it is a multifactorial, polygenic autoimmune disease with HLA-driven susceptibility (e.g., HLA-DRB1*03:01). Penetrance, expressivity, anticipation, and carrier-frequency concepts do not apply.
Show evidence (1 reference)
PMID:33301929 SUPPORT Human Clinical
"A statistically significant increase of HLA-DRB1*03:01 and HLA-B*08:01 alleles in patients with ASSD compared to healthy controls was disclosed"
Supports HLA susceptibility rather than a Mendelian inheritance model; the excerpt does not by itself prove the absence of rare familial aggregation.
?

Discussions and Knowledge Gaps

3
Which anti-aaRS antibodies are directly pathogenic in vivo, and through which antigen-, cell-, and organ-specific routes?
KNOWLEDGE GAP OPEN asys_autoantibody_pathogenicity
Attached to
pathophysiology#Loss of Tolerance to Aminoacyl-tRNA Synthetases pathophysiology#tRNA-Triggered Toll-Like Receptor and Interferon Amplification pathophysiology#HARS Immune-Complex Activation of Alveolar Monocyte-Macrophages
Reviews describe the antibody roles as unclear. The 2026 human multi-omics and in-vitro study strengthens a HARS immune-complex/macrophage route but is small and does not establish in-vivo causality or generalization across anti-aaRS specificities.
Show evidence (1 reference)
PMID:36280495 SUPPORT Other
"Although these autoantibodies are believed to play critical roles in ASSD pathogenesis, the nature of their roles remains unclear."
The mechanistic review explicitly identifies the unresolved pathogenic role.
Which immunosuppressive strategy provides the best benefit-risk profile for initial, progressive, and rapidly progressive antisynthetase-syndrome ILD?
KNOWLEDGE GAP OPEN asys_treatment_comparative_evidence
Attached to
treatments#Rituximab treatments#Cyclophosphamide treatments#Tacrolimus
Available outcome evidence is dominated by retrospective series and heterogeneous regimens. The registered CATR.PAT randomized comparison has unknown registry status and no represented results, so comparative efficacy remains unresolved.
Show evidence (1 reference)
PMID:39083028 SUPPORT Other
"found no conclusive difference between effectiveness of treatments. More robust trials are required to reduce morbidity and mortality resulting from ASS-ILD."
The systematic review states the comparative-evidence limitation directly.
Which combination of serology and manifestations will yield validated, generalizable antisynthetase-syndrome classification criteria?
KNOWLEDGE GAP OPEN asys_classification_criteria
Attached to
diagnosis#Anti-Aminoacyl-tRNA Synthetase Antibody Testing
Connors and Solomon are historical proposals. The large international CLASS project has identified discriminating variables, but the cited publication does not present completed validated criteria.
Show evidence (1 reference)
PMID:39467037 SUPPORT Human Clinical
"Anti-synthetase syndrome (ASSD) is a rare systemic autoimmune rheumatic disease (SARD) with significant heterogeneity and no shared classification criteria."
Directly supports the open classification-criteria gap.
⚙

Pathophysiology

7
Loss of Tolerance to Aminoacyl-tRNA Synthetases
The defining upstream event is breakdown of immune tolerance to one of the cytoplasmic aminoacyl-tRNA synthetase (aaRS) enzymes, generating circulating anti-aaRS autoantibodies. These antibodies are defining biomarkers and plausible mechanistic participants, but their precise pathogenic contribution is not yet established. The aaRS enzymes are housekeeping enzymes whose native role is tRNA aminoacylation.
HLA-DRB1 hgnc:4948 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves HLA-DRB1 (hgnc:4948). hgnc:4948 is a gene from the HUGO Gene Nomenclature Committee. HARS1 hgnc:4816 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves HARS1 (hgnc:4816). hgnc:4816 is a gene from the HUGO Gene Nomenclature Committee. TARS1 hgnc:11572 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves TARS1 (hgnc:11572). hgnc:11572 is a gene from the HUGO Gene Nomenclature Committee. AARS1 hgnc:20 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves AARS1 (hgnc:20). hgnc:20 is a gene from the HUGO Gene Nomenclature Committee. GARS1 hgnc:4162 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves GARS1 (hgnc:4162). hgnc:4162 is a gene from the HUGO Gene Nomenclature Committee. IARS1 hgnc:5330 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves IARS1 (hgnc:5330). hgnc:5330 is a gene from the HUGO Gene Nomenclature Committee. NARS1 hgnc:7643 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves NARS1 (hgnc:7643). hgnc:7643 is a gene from the HUGO Gene Nomenclature Committee.
Aminoacyl-tRNA ligase activity (autoantigen native function) GO:0004812 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves Aminoacyl-tRNA ligase activity (autoantigen native function), annotated with aminoacyl-tRNA ligase activity (GO:0004812). GO:0004812 is a molecular function from the Gene Ontology.
Downstream
Tissue-Specific Secretion of Aminoacyl-tRNA Synthetases
Show evidence (1 reference)
PMID:36280495 SUPPORT Other
"Antisynthetase syndrome (ASSD) is an autoimmune disease characterized by circulating autoantibodies against one of eight aminoacyl-tRNA synthetases"
Establishes that the disease is defined by autoantibodies against the aaRS enzymes, the serological hallmark and upstream immune lesion.
Tissue-Specific Secretion of Aminoacyl-tRNA Synthetases
Damaged or regenerating muscle and inflamed lung secrete certain aaRS enzymes extracellularly; this tissue-specific secretion is proposed as a key determinant of which aaRS becomes an autoantigen, exposing the enzyme to the immune system outside its normal cytoplasmic compartment.
Skeletal muscle cell CL:0000188 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Skeletal muscle cell, annotated with cell of skeletal muscle (CL:0000188). CL:0000188 is a cell type from the Cell Ontology. Alveolar macrophage CL:0000583 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Alveolar macrophage (CL:0000583). CL:0000583 is a cell type from the Cell Ontology.
Aminoacyl-tRNA ligase activity (secreted autoantigen) GO:0004812 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves Aminoacyl-tRNA ligase activity (secreted autoantigen), annotated with aminoacyl-tRNA ligase activity (GO:0004812). GO:0004812 is a molecular function from the Gene Ontology.
Downstream
tRNA-Triggered Toll-Like Receptor and Interferon Amplification
Show evidence (1 reference)
PMID:36280495 SUPPORT Other
"we propose that ASSD pathogenesis involves the tissue-specific secretion of aaRSs"
Supports extracellular, tissue-specific secretion of aaRS enzymes as a proximal step that makes the housekeeping enzyme available as an autoantigen.
tRNA-Triggered Toll-Like Receptor and Interferon Amplification
Anti-aaRS antibodies bind the synthetase together with bound tRNA or tRNA fragments, forming immune complexes that are internalized into endosomes where the nucleic-acid cargo engages Toll-like receptor signaling and drives type I interferon release - a self-amplifying innate-plus-adaptive loop that perpetuates autoantibody production and tissue inflammation.
Dendritic cell CL:0000451 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Dendritic cell (CL:0000451). CL:0000451 is a cell type from the Cell Ontology. Monocyte CL:0000576 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Monocyte (CL:0000576). CL:0000576 is a cell type from the Cell Ontology.
Toll-like receptor signaling pathway GO:0002224 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Toll-like receptor signaling pathway (GO:0002224). GO:0002224 is a biological process from the Gene Ontology. ↑ INCREASED Type I interferon production GO:0032606 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Type I interferon production (GO:0032606). GO:0032606 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Autoantibody and Cytotoxic Immune Effector Production
Show evidence (1 reference)
PMID:36280495 SUPPORT Other
"extracellular tRNAs or tRNA fragments and their ability to engage Toll-like receptor signaling may be important disease factors"
Supports tRNA-driven Toll-like receptor engagement as an innate-immune amplification mechanism in disease pathogenesis.
Autoantibody and Cytotoxic Immune Effector Production
aaRS-specific CD4+ T-cell help drives B cells and plasma cells to produce class-switched anti-aaRS autoantibodies, while cytotoxic effector cells are recruited; the adaptive response targets aaRS-expressing or aaRS-secreting tissues (lung, muscle, joint).
CD4+ T cell CL:0000624 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves CD4+ T cell, annotated with CD4-positive, alpha-beta T cell (CL:0000624). CL:0000624 is a cell type from the Cell Ontology. B cell CL:0000236 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves B cell (CL:0000236). CL:0000236 is a cell type from the Cell Ontology. Plasma cell CL:0000786 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Plasma cell (CL:0000786). CL:0000786 is a cell type from the Cell Ontology.
Immunoglobulin production GO:0002377 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Immunoglobulin production (GO:0002377). GO:0002377 is a biological process from the Gene Ontology. ↑ INCREASED Adaptive immune response GO:0002250 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Adaptive immune response (GO:0002250). GO:0002250 is a biological process from the Gene Ontology.
Downstream
HARS Immune-Complex Activation of Alveolar Monocyte-Macrophages
Immune-Mediated Myofiber Injury
Inflammatory Arthritis
Mechanic's Hands
Raynaud Phenomenon
Unexplained Fever
Show evidence (1 reference)
PMID:36280495 SUPPORT Other
"these autoantibodies are believed to play critical roles in ASSD pathogenesis"
Supports the central pathogenic role of the produced anti-aaRS autoantibodies in driving tissue-targeted disease.
HARS Immune-Complex Activation of Alveolar Monocyte-Macrophages
In a small 2026 paired blood/BALF multi-omics study, inflammatory monocyte-macrophage populations were expanded in antisynthetase-syndrome ILD, and HARS-containing immune complexes activated primary human macrophages in vitro. This provides provisional, anti-Jo-1-specific support for an immune-complex-to-lung inflammation route; it does not establish that this mechanism explains other anti-synthetase specificities or clinical outcomes.
Macrophage CL:0000235 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Macrophage (CL:0000235). CL:0000235 is a cell type from the Cell Ontology.
HARS1 hgnc:4816 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves HARS1 (hgnc:4816). hgnc:4816 is a gene from the HUGO Gene Nomenclature Committee.
Macrophage activation GO:0042116 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Macrophage activation (GO:0042116). GO:0042116 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Immune-Mediated Alveolar Injury and Interstitial Lung Disease
Show evidence (2 references)
PMID:42121132 SUPPORT Human Clinical
"In ASS-ILD BALF, monocyte-macrophages showed significantly higher cytokine and inflammatory gene module scores compared with IPF and HCs"
Supports activated alveolar monocyte-macrophage populations in the human lung; only four patients contributed to the single-cell analysis.
PMID:42121132 SUPPORT In Vitro
"In vitro, human histidyl ARS-containing immune complexes (IC) induced higher expression of MHC-I/II, CD80/CD86, pro-inflammatory cytokines, and ARS genes in primary human macrophages compared with control IC."
Directly supports macrophage activation by HARS-containing immune complexes in vitro, without establishing in-vivo causality.
Immune-Mediated Alveolar Injury and Interstitial Lung Disease
Immune effectors and interferon programs injure the alveolar interstitium, producing interstitial lung inflammation that can progress to fibrosis (NSIP > organizing pneumonia > UIP patterns). ILD frequently predominates at presentation and is the principal driver of morbidity and mortality.
Type II pneumocyte CL:0002063 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Type II pneumocyte, annotated with pulmonary alveolar type 2 cell (CL:0002063). CL:0002063 is a cell type from the Cell Ontology. Pulmonary interstitial fibroblast CL:0000057 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Pulmonary interstitial fibroblast, annotated with fibroblast (CL:0000057). CL:0000057 is a cell type from the Cell Ontology.
Inflammatory response GO:0006954 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Inflammatory response (GO:0006954). GO:0006954 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Interstitial Lung Disease
Dyspnea
Pulmonary Fibrosis
Pulmonary Hypertension Secondary to ILD
Show evidence (1 reference)
PMID:27594777 SUPPORT Human Clinical
"The ILD in anti-synthetase syndrome patients is often severe and rapidly progressive, causing much of the increased morbidity and mortality associated with anti-synthetase syndrome as compared to the other IIMs"
Supports interstitial lung disease as the dominant, prognosis-determining tissue injury in the syndrome.
Immune-Mediated Myofiber Injury
Skeletal myofibers undergo immune-mediated injury with characteristic perimysial fragmentation, perifascicular necrosis, and aberrant sarcolemmal MHC class I upregulation, producing inflammatory myositis with proximal muscle weakness and elevated muscle enzymes.
Skeletal muscle cell CL:0000188 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Skeletal muscle cell, annotated with cell of skeletal muscle (CL:0000188). CL:0000188 is a cell type from the Cell Ontology. CD8+ cytotoxic T cell CL:0000625 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves CD8+ cytotoxic T cell, annotated with CD8-positive, alpha-beta T cell (CL:0000625). CL:0000625 is a cell type from the Cell Ontology.
MHC class I antigen processing and presentation GO:0002474 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased MHC class I antigen processing and presentation, annotated with antigen processing and presentation of peptide antigen via MHC class I (GO:0002474). GO:0002474 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Inflammatory Myositis
Proximal Muscle Weakness
Dysphagia
Myalgia
Elevated Creatine Kinase
Show evidence (1 reference)
PMID:36280495 SUPPORT Other
"Although these autoantibodies are believed to play critical roles in ASSD pathogenesis, the nature of their roles remains unclear."
Supports the autoantibody-centered immune mechanism underlying tissue (including muscle) injury, while flagging residual mechanistic uncertainty.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Antisynthetase Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

13
Cardiovascular 1
Raynaud Phenomenon HP:0030880 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Raynaud phenomenon (HP:0030880). HP:0030880 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:27594777 SUPPORT Human Clinical
"clinical features that may include interstitial lung disease (ILD), non-erosive arthritis, myositis, Raynaud’s phenomenon, unexplained fever and/or mechanic’s hands"
Supports Raynaud phenomenon as a recognized clinical feature of the syndrome.
Digestive 1
Dysphagia HP:0002015 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dysphagia (HP:0002015). HP:0002015 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28586844 SUPPORT Human Clinical
"All 51 patients presented with muscle limb weakness; 14 (27%) had severe limb weakness, 17 (33%) had neck muscle weakness, 15 (29%) had dysphagia, and 15 (29%) had muscle atrophy."
Supports dysphagia in a selected anti-ARS-positive muscle-biopsy cohort; the 29% estimate is not generalized to all antisynthetase syndrome.
Metabolism 2
Unexplained Fever HP:0001945 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Fever (HP:0001945). HP:0001945 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:27594777 SUPPORT Human Clinical
"clinical features that may include interstitial lung disease (ILD), non-erosive arthritis, myositis, Raynaud’s phenomenon, unexplained fever and/or mechanic’s hands"
Supports unexplained fever as a recognized clinical feature of the syndrome.
Elevated Creatine Kinase Elevated circulating creatine kinase concentration HP:0003236 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Elevated circulating creatine kinase concentration (HP:0003236). HP:0003236 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:27594777 SUPPORT Human Clinical
"presence should prompt further testing for anti-synthetase antibodies and elevated muscle enzymes"
Supports elevated muscle enzymes (creatine kinase) as a laboratory feature prompted by the syndrome's findings.
Musculoskeletal 3
Inflammatory Myositis FREQUENT Myopathy HP:0003198 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Myopathy (HP:0003198). HP:0003198 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:27594777 SUPPORT Human Clinical
"In a 2013 study of 203 anti-synthetase syndrome patients, the prevalence of ILD was 86%, more common than the prevalence of myositis (73%) or arthralgia/arthritis (60%)"
Supports the association and a frequent (30-79%) frequency band for myositis.
Proximal Muscle Weakness HP:0003701 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Proximal muscle weakness (HP:0003701). HP:0003701 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:27594777 SUPPORT Human Clinical
"the prevalence of muscle symptoms (weakness and myalgia) was significantly lower in patients with anti-PL7/PL12 as compared to those with anti-Jo1"
Supports muscle weakness as a manifestation of the syndrome (more frequent in anti-Jo-1 disease).
Inflammatory Arthritis FREQUENT HP:0001369 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Arthritis (HP:0001369). HP:0001369 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:27594777 SUPPORT Human Clinical
"In a 2013 study of 203 anti-synthetase syndrome patients, the prevalence of ILD was 86%, more common than the prevalence of myositis (73%) or arthralgia/arthritis (60%)"
Supports the association and a frequent (30-79%) frequency band for arthralgia/arthritis.
Respiratory 2
Dyspnea HP:0002094 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dyspnea (HP:0002094). HP:0002094 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:27594777 SUPPORT Human Clinical
"decreased survival was seen in patients without muscle weakness and with severe dyspnea"
Supports dyspnea (from ILD) as a clinically important manifestation associated with worse survival.
Pulmonary Fibrosis HP:0002206 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pulmonary fibrosis (HP:0002206), qualified as course progressive. HP:0002206 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:27594777 SUPPORT Human Clinical
"The most common causes of death were pulmonary fibrosis and pulmonary hypertension"
Supports pulmonary fibrosis as a fibrotic ILD outcome and a leading cause of death in the syndrome.
Constitutional 1
Myalgia HP:0003326 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Myalgia (HP:0003326). HP:0003326 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:27594777 SUPPORT Human Clinical
"the prevalence of muscle symptoms (weakness and myalgia) was significantly lower in patients with anti-PL7/PL12 as compared to those with anti-Jo1"
Supports myalgia as a muscle symptom of the syndrome.
Other 3
Interstitial Lung Disease VERY_FREQUENT Interstitial pneumonitis HP:0006515 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Interstitial lung disease, annotated with Interstitial pneumonitis (HP:0006515), qualified as course progressive. HP:0006515 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:27594777 SUPPORT Human Clinical
"In a 2013 study of 203 anti-synthetase syndrome patients, the prevalence of ILD was 86%, more common than the prevalence of myositis (73%) or arthralgia/arthritis (60%)"
Supports both the association and a very-frequent (>80%) frequency band for ILD in antisynthetase syndrome.
Mechanic's Hands HP:6001013 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Mechanic's hands (HP:6001013). HP:6001013 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:27594777 SUPPORT Human Clinical
"the hyperkeratosis and scaling characteristic of mechanic’s hands are often subtle findings whose presence should prompt further testing for anti-synthetase antibodies"
Supports mechanic's hands (finger hyperkeratosis/scaling) as a characteristic cutaneous feature of the syndrome.
Pulmonary Hypertension Secondary to ILD
Show evidence (1 reference)
PMID:39467037 SUPPORT Human Clinical
"Specific variables associated with ASSD included arthritis, diffuse myalgia, muscle weakness, muscle enzyme elevation, ILD, mechanic's hands, secondary pulmonary hypertension due to ILD, Raynaud phenomenon, and unexplained fever."
Supports secondary pulmonary hypertension due to ILD in a large international case-control classification cohort.
🧬

Genetic Associations

8
HLA-DRB1 (8.1 ancestral haplotype) susceptibility (Risk Factor)
Gene: HLA-DRB1 hgnc:4948 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is HLA-DRB1 (hgnc:4948). hgnc:4948 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SUSCEPTIBILITY
Show evidence (2 references)
PMID:33301929 SUPPORT Human Clinical
"A statistically significant increase of HLA-DRB1*03:01 and HLA-B*08:01 alleles in patients with ASSD compared to healthy controls was disclosed"
Directly supports HLA-DRB1*03:01 (and linked HLA-B*08:01 of the 8.1 haplotype) as a susceptibility allele for antisynthetase syndrome.
PMID:33301929 SUPPORT Human Clinical
"a statistically significant increase of HLA-DRB1*03:01 allele in anti-Jo-1 positive compared to anti-Jo-1 negative patients with ASSD was observed"
Supports the particularly strong HLA-DRB1*03:01 association with anti-Jo-1-positive disease.
HARS1 (autoantigen; anti-Jo-1 target) (Autoantigen)
Gene: HARS1 hgnc:4816 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is HARS1 (hgnc:4816). hgnc:4816 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
PMID:35634293 SUPPORT Other
"Histidyl-tRNA Class II HisRS Jo-1 HARS"
The review's autoantigen table maps histidyl-tRNA synthetase/HARS to anti-Jo-1.
TARS1 (autoantigen; anti-PL-7 target) (Autoantigen)
Gene: TARS1 hgnc:11572 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is TARS1 (hgnc:11572). hgnc:11572 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
PMID:35634293 SUPPORT Other
"Threonyl-tRNA Class II ThrRS PL-7 TARS"
The review's autoantigen table maps threonyl-tRNA synthetase/TARS to anti-PL-7.
AARS1 (autoantigen; anti-PL-12 target) (Autoantigen)
Gene: AARS1 hgnc:20 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is AARS1 (hgnc:20). hgnc:20 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
PMID:35634293 SUPPORT Other
"Alanyl-tRNA Class II AlaRS PL-12 AARS"
The review's autoantigen table maps alanyl-tRNA synthetase/AARS to anti-PL-12.
GARS1 (autoantigen; anti-EJ target) (Autoantigen)
Gene: GARS1 hgnc:4162 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is GARS1 (hgnc:4162). hgnc:4162 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
PMID:35634293 SUPPORT Other
"Glycyl-tRNA Class II GlyRS EJ GARS"
The review's autoantigen table maps glycyl-tRNA synthetase/GARS to anti-EJ.
IARS1 (autoantigen; anti-OJ target) (Autoantigen)
Gene: IARS1 hgnc:5330 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is IARS1 (hgnc:5330). hgnc:5330 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
PMID:35634293 SUPPORT Other
"Isoleucyl-tRNA Class II IleRS OJ IARS"
The review's autoantigen table maps isoleucyl-tRNA synthetase/IARS to anti-OJ.
NARS1 (autoantigen; anti-KS target) (Autoantigen)
Gene: NARS1 hgnc:7643 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is NARS1 (hgnc:7643). hgnc:7643 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
PMID:35634293 SUPPORT Other
"Asparaginyl-tRNA Class II AsnRS KS NARS"
The review's autoantigen table maps asparaginyl-tRNA synthetase/NARS to anti-KS.
TRIM21 (autoantigen; anti-Ro52 target) (Autoantigen)
Gene: TRIM21 hgnc:11312 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is TRIM21 (hgnc:11312). hgnc:11312 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: BIOMARKER
Show evidence (1 reference)
PMID:28339994 SUPPORT Human Clinical
"Concurrent anti-Ro52 was more prevalent in anti-Jo1 patients and was associated with earlier development of mechanic's hands, DM-specific skin findings and arthritis"
Supports TRIM21/Ro52 as a co-autoantigen biomarker associated with phenotype, not as a causal disease gene.
💊

Medical Actions

8
Corticosteroids
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: prednisone CHEBI:8382 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses prednisone (CHEBI:8382). CHEBI:8382 is a therapeutic agent from Chemical Entities of Biological Interest. prednisolone CHEBI:8378 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses prednisolone (CHEBI:8378). CHEBI:8378 is a therapeutic agent from Chemical Entities of Biological Interest.
First-line therapy for active muscle and/or lung disease. Corticosteroid monotherapy is frequently insufficient (lung disease recurs with tapering), so adjunctive immunosuppression is usually added.
Mechanism Target:
Immune-Mediated Alveolar Injury and Interstitial Lung Disease — Broad anti-inflammatory/immunosuppressive control of the alveolar inflammation.
Show evidence (1 reference)
PMID:38973731 SUPPORT Other
"glucocorticoids are conditionally recommended for first-line ILD treatment in all other SARDs."
Supports targeting SARD-ILD clinically, not the detailed molecular mechanism.
Show evidence (2 references)
PMID:27594777 SUPPORT Human Clinical
"Corticosteroids have long been first-line in the treatment of IIMs, though when corticosteroids are used as monotherapy in anti-synthetase syndrome, there is frequent lung disease recurrence with corticosteroid tapering"
Supports corticosteroids as first-line and the rationale for adding steroid-sparing agents.
PMID:38973731 SUPPORT Other
"glucocorticoids are conditionally recommended for first-line ILD treatment in all other SARDs."
Provides an authoritative conditional recommendation for glucocorticoids in non-systemic-sclerosis SARD-ILD; it is not specific to antisynthetase syndrome.
Mycophenolate Mofetil
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: mycophenolate mofetil CHEBI:8764 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses mycophenolate mofetil (CHEBI:8764). CHEBI:8764 is a therapeutic agent from Chemical Entities of Biological Interest.
A frequently used adjunctive steroid-sparing immunosuppressant; inhibits proliferating lymphocytes by altering purine synthesis. Often combined with prednisone for ILD.
Mechanism Target:
Autoantibody and Cytotoxic Immune Effector Production — Suppresses proliferating lymphocytes driving the autoimmune effector response.
Show evidence (1 reference)
PMID:27594777 SUPPORT Human Clinical
"Frequently used adjunctive agents include azathioprine, mycophenolate mofetil, tacrolimus, rituximab, and cyclophosphamide"
Supports clinical use of mycophenolate as immunosuppression, not this molecular target assignment directly.
Show evidence (1 reference)
PMID:27594777 SUPPORT Human Clinical
"Frequently used adjunctive agents include azathioprine, mycophenolate mofetil, tacrolimus, rituximab, and cyclophosphamide"
Supports mycophenolate mofetil as a frequently used adjunctive immunosuppressant.
Azathioprine
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: azathioprine CHEBI:2948 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses azathioprine (CHEBI:2948). CHEBI:2948 is a therapeutic agent from Chemical Entities of Biological Interest.
Adjunctive steroid-sparing immunosuppressant; halts purine synthesis. Most frequently used as maintenance therapy in conjunction with prednisone.
Show evidence (1 reference)
PMID:27594777 SUPPORT Human Clinical
"azathioprine has been most frequently used as maintenance therapy often in conjunction with prednisone"
Supports azathioprine as a maintenance steroid-sparing agent.
Tacrolimus
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: tacrolimus CHEBI:61049 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses tacrolimus, annotated with tacrolimus (anhydrous) (CHEBI:61049). CHEBI:61049 is a therapeutic agent from Chemical Entities of Biological Interest.
Calcineurin inhibitor used as add-on therapy, particularly for more severe ILD; case series in antisynthetase-syndrome-ILD show improved lung function and reduced corticosteroid dose.
Mechanism Target:
Autoantibody and Cytotoxic Immune Effector Production — Calcineurin inhibition suppresses T-cell-driven autoimmune effector activity.
Show evidence (1 reference)
PMID:27594777 SUPPORT Human Clinical
"A 2005 case series specifically studied tacrolimus efficacy in 15 patients with anti-synthetase syndrome-ILD."
Supports clinical use in the disease but not the mechanistic target assignment directly.
Show evidence (1 reference)
PMID:27594777 SUPPORT Human Clinical
"A 2005 case series specifically studied tacrolimus efficacy in 15 patients with anti-synthetase syndrome-ILD. Most of these patients had Jo-1 autoantibodies, and experienced improvement in lung function and muscle symptoms"
Supports tacrolimus as an effective add-on for antisynthetase-syndrome-ILD.
Rituximab
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: rituximab NCIT:C1702 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses rituximab (NCIT:C1702). NCIT:C1702 is a therapeutic agent from the NCI Thesaurus.
Anti-CD20 monoclonal antibody depleting B cells; used for severe, progressive, or refractory ILD ("rescue therapy"), with case series showing FVC improvement.
Mechanism Target:
Autoantibody and Cytotoxic Immune Effector Production — B-cell depletion reduces autoantibody-producing plasma-cell precursors.
Show evidence (1 reference)
PMID:27594777 SUPPORT Human Clinical
"In the setting of anti-synthetase syndrome, we use rituximab for patients with severe progressive and/or refractory ILD"
Supports disease use of a B-cell-directed agent, not direct measurement of the modeled mechanism.
Show evidence (2 references)
PMID:27594777 SUPPORT Human Clinical
"In the setting of anti-synthetase syndrome, we use rituximab for patients with severe progressive and/or refractory ILD"
Supports rituximab for severe progressive/refractory antisynthetase-syndrome ILD.
PMID:39083028 SUPPORT Other
"Patients receiving rituximab had 12.2% improvement in FVC and 2.9% increase in DLco at 1 year; for patients receiving CYC, there was 17% improvement and 6.3% increase, respectively."
Summarizes observed pulmonary-function improvement, while the review found no conclusive comparative treatment difference and called for robust trials.
Cyclophosphamide
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: cyclophosphamide CHEBI:4027 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses cyclophosphamide (CHEBI:4027). CHEBI:4027 is a therapeutic agent from Chemical Entities of Biological Interest.
Cytotoxic alkylating agent reserved for severe IIM-ILD, particularly acute respiratory distress syndrome / rapidly progressive ILD, given its toxicity profile.
Show evidence (2 references)
PMID:27594777 SUPPORT Human Clinical
"have used cyclophosphamide in ARDS"
Supports cyclophosphamide reserved for severe/ARDS-like antisynthetase-syndrome ILD.
PMID:39083028 SUPPORT Other
"Patients receiving rituximab had 12.2% improvement in FVC and 2.9% increase in DLco at 1 year; for patients receiving CYC, there was 17% improvement and 6.3% increase, respectively."
Summarizes observed cyclophosphamide-associated pulmonary-function improvement; heterogeneous non-randomized evidence does not establish comparative superiority.
Intravenous Immunoglobulin (IVIG)
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Pooled donor IgG used as adjunctive therapy, especially for refractory myositis; a case report suggests possible benefit in IIM-related ILD.
Show evidence (1 reference)
PMID:27594777 SUPPORT Human Clinical
"A recent case report suggested IVIG may be effective in ILD related to IIM as well"
Supports only case-report-level possible benefit in IIM-related ILD, not established antisynthetase-syndrome efficacy or the refractory-myositis qualifier.
Lung Transplantation
Action: organ transplantationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is organ transplantation (NCIT:C15289). NCIT:C15289 is a clinical intervention from the NCI Thesaurus. Ontology label: Organ Transplantation NCIT:C15289
Reserved for end-stage progressive interstitial lung disease refractory to medical therapy.
Show evidence (1 reference)
PMID:27594777 SUPPORT Human Clinical
"progressive interstitial lung disease necessitating lung transplantation"
Supports lung transplantation for end-stage progressive ILD.
🔬

Biochemical Markers

3
Anti-Jo-1 (Anti-Histidyl-tRNA Synthetase) Autoantibody (Elevated)
Context: The most common anti-aminoacyl-tRNA synthetase antibody; defines the classic, more myositis-predominant phenotype. Antibody titer correlates with disease activity.
Show evidence (1 reference)
PMID:28339994 SUPPORT Human Clinical
"One hundred and twenty-four (73.4%) patients were positive for anti-Jo1"
Supports anti-Jo-1 as the most frequent anti-synthetase antibody in an antisynthetase-syndrome cohort.
Anti-PL-7 / Anti-PL-12 (and other non-Jo-1 anti-ARS) Autoantibodies (Elevated)
Context: Non-Jo-1 anti-aminoacyl-tRNA synthetase antibodies (anti-PL-7/TARS1, anti-PL-12/AARS1, anti-EJ/GARS1, anti-OJ/IARS1, anti-KS/NARS1) are associated with more lung-predominant, often amyopathic disease.
Show evidence (1 reference)
PMID:22771754 SUPPORT Human Clinical
"ILD was more frequent (80% and 88% vs 67%, p=0.014) whereas myositis was less common (44% and 47% vs 74%, p<0.001) in patients with anti-PL7 and anti-PL12 compared to anti-Jo1"
Supports the lung-predominant, less-myopathic phenotype of anti-PL-7/anti-PL-12 versus anti-Jo-1.
Anti-Ro52 (TRIM21) Co-Antibody (Elevated)
Context: Frequently co-positive with anti-synthetase antibodies; in one cohort it was more prevalent in anti-Jo-1-positive disease and linked to earlier mechanic's hands, DM-specific skin findings, and arthritis.
Show evidence (1 reference)
PMID:28339994 SUPPORT Human Clinical
"Concurrent anti-Ro52 was more prevalent in anti-Jo1 patients and was associated with earlier development of mechanic's hands, DM-specific skin findings and arthritis"
Supports anti-Ro52 co-positivity as a phenotype-modifying serology.
🔬

Diagnosis

2
Anti-Aminoacyl-tRNA Synthetase Antibody Testing
The serological cornerstone of diagnosis. Connors (2010) and Solomon (2011) proposed historical classification frameworks combining an anti-tRNA-synthetase autoantibody with compatible clinical features. They should not be represented as universally accepted diagnostic criteria; the international CLASS project is developing data-driven classification criteria.
Show evidence (2 references)
PMID:27594777 SUPPORT Human Clinical
"These criteria proposed that all patients with anti-synthetase syndrome must have evidence for a tRNA synthetase autoantibody, in addition to one or more of the following clinical features: mechanic’s hands, Raynaud’s phenomenon, myositis, ILD, arthritis, and/or unexplained fever"
Supports the components of the historical Connors proposal, not universal validation.
PMID:39467037 SUPPORT Human Clinical
"Anti-synthetase syndrome (ASSD) is a rare systemic autoimmune rheumatic disease (SARD) with significant heterogeneity and no shared classification criteria."
Establishes the current lack of shared validated classification criteria and the purpose of the international CLASS effort.
High-Resolution Chest CT and Pulmonary Function Testing
HRCT characterizes the ILD pattern (NSIP/OP/UIP); pulmonary function tests with DLCO assess restriction and diffusion and are used for serial monitoring.
Show evidence (1 reference)
PMID:27594777 SUPPORT Human Clinical
"Diagnosis is made by a multidisciplinary approach, synthesizing rheumatology and pulmonary evaluations, along with serologic, radiographic, and occasionally muscle and/or lung biopsy results"
Supports the multidisciplinary, serologic/radiographic/biopsy-based diagnostic workup.
📈

Progression

1
Accrual of Manifestations and ILD-Driven Course
Adult-onset (peak 5th-6th decade), subacute-to-chronic and insidious; manifestations accrue over time from "incomplete" to "complete" syndrome. Course is chronic and relapsing, with ILD severity (especially fibrotic progression) determining prognosis. Phenotype and survival correlate with anti-ARS antibody specificity (worse with anti-PL-7/PL-12 than anti-Jo-1).
Show evidence (2 references)
PMID:22771754 SUPPORT Human Clinical
"In patients with ASS, the phenotype and the survival were correlated with the anti-ARS specificity."
Supports antibody-specificity-dependent phenotype and survival.
PMID:41376133 SUPPORT Human Clinical
"In our study, 39% of patients had RP-ILD at ILD diagnosis."
Supports a clinically important rapidly progressive ILD subgroup in a 132-patient multicenter ASyS-ILD cohort; it is not an all-ASyS frequency estimate.
🌍

Epidemiology

1
Incidence and Prevalence
A rare disease. In a US population-based cohort (Olmsted County, Minnesota, 1998-2019), the age- and sex-adjusted incidence was 0.56 per 100,000 and point prevalence 9.21 per 100,000. No significant increase in malignancy risk was observed in this and another cohort.
Show evidence (2 references)
PMID:39814448 SUPPORT Human Clinical
"The age- and sex-adjusted incidence of ASS was 0.56 (95% CI 0.25-0.87) per 100,000 population."
Supports the population-based incidence estimate.
PMID:28339994 SUPPORT Human Clinical
"There was no significant increase in mortality or cancer risk in ASyS patients compared with the general US population."
Supports the comparatively low malignancy/mortality risk relative to classic dermatomyositis.
🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from Antisynthetase Syndrome:

Polymyositis and Dermatomyositis
Overlapping Features Other idiopathic inflammatory myopathies with which antisynthetase syndrome overlaps; historically these patients were diagnosed as PM or DM.
Distinguishing Features
  • Antisynthetase syndrome is defined by anti-aminoacyl-tRNA synthetase antibodies and has a higher prevalence and severity of ILD than DM/PM.
  • It lacks the defining DM skin signs (heliotrope rash, Gottron papules) unless in overlap.
  • Muscle biopsy shows perimysial fragmentation/perifascicular necrosis distinct from DM perifascicular atrophy and PM endomysial CD8 invasion.
Show evidence (1 reference)
PMID:27594777 SUPPORT Human Clinical
"There is a higher prevalence and increased severity of interstitial lung disease in patients with anti-synthetase syndrome, as compared to dermatomyositis and polymyositis"
Supports the ILD-predominance distinction from DM/PM.
Idiopathic Interstitial Pneumonia (e.g., IPF / idiopathic NSIP)
Overlapping Features Antisynthetase-syndrome ILD can present as apparently idiopathic interstitial pneumonia before the autoimmune basis is recognized.
Distinguishing Features
  • A myositis-antibody panel reveals an anti-synthetase antibody; in one retrospective analysis of 198 idiopathic interstitial pneumonia patients, 13 were later found to have an anti-synthetase antibody.
Show evidence (1 reference)
PMID:27594777 SUPPORT Human Clinical
"in a recent retrospective analysis of 198 patients with idiopathic interstitial pneumonia, 13 patients were later noted to have an anti-synthetase antibody"
Supports the need to differentiate antisynthetase ILD from idiopathic interstitial pneumonia by antibody testing.
📊

Related Datasets

1
Spatial and cell type specific molecular genetic investigations of inflammatory myopathies with selective perifascicular injury. geo:GSE330891
Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of systemic autoimmune disease often with multisystem involvement. Targeted therapy is still lacking. Efficient serum or histological markers to measure disease activity and predict disease course are missing. Perifascicular myofiber atrophy is a hall mark of dermatomyositis (DM). Despite decades of research, the mechanism of perifascicular atrophy is still incompletely understood. Across other IIM subtypes, perifascicular myofiber necrosis is also the hall mark pathology for antisynthetase syndrome associated myositis (ASyS)5, and can be seen in a subset of lupus myositis (LM).
human SPATIAL TRANSCRIPTOMICS n=301
PMID:42427858
Identified by GEO DataSets index search for Antisynthetase Syndrome (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
🔬

Clinical Trials

2
NCT03770663 PHASE_III UNKNOWN
CATR.PAT is a registered 52-week randomized, controlled, open-label comparison of cyclophosphamide followed by azathioprine versus tacrolimus for first-line or relapsing antisynthetase-syndrome ILD. As of the 2026-08-05 audit, the registry status is unknown and no results are represented here; registration is not evidence of efficacy.
Target Phenotypes: Interstitial lung disease HP:0006515 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Interstitial lung disease, annotated with Interstitial pneumonitis (HP:0006515). HP:0006515 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
clinicaltrials:NCT03770663 SUPPORT Human Clinical
"CATR.PAT study is a 52 weeks, randomized, comparative, controlled, open-labeled, phase III, therapeutic clinical trial, comparing two treatment strategies."
Supports the registered design and comparison, not completion or treatment effect.
NCT01276470 NOT_APPLICABLE RECRUITING
Observational case-control research comparing pre-onset infectious and noninfectious environmental exposures among people with myositis with antisynthetase antibodies, other myositis, and healthy volunteers. The current registry listed recruiting at the 2026-08-05 audit; no causal exposure result is asserted.
Show evidence (1 reference)
clinicaltrials:NCT01276470 SUPPORT Human Clinical
"To determine whether selected infectious and noninfectious environmental exposures are more common in individuals who have myositis with the anti-synthetase syndrome, compared with healthy volunteers."
Supports the observational study objective, not any environmental causal claim.
🐁

Animal Models

1
Wild-type C57BL/6 and NOD congenic mice immunized with murine Jo-1 protein Mus musculus
Immunization with murine histidyl-tRNA synthetase generated Jo-1-specific adaptive immunity and combined muscle and lung inflammation. The inducible, anti-Jo-1-specific model supports antigen-directed pathogenicity but does not reproduce chronic human multisystem disease or non-Jo-1 subtypes.
Inflammatory Myositis Interstitial Lung Disease
Species
Mus musculus
Genotype
Wild-type C57BL/6 and NOD congenic mice immunized with murine Jo-1 protein
Genes
Hars1 hgnc:4816 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns Hars1 (hgnc:4816). hgnc:4816 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
PMID:17826948 SUPPORT Model Organism
"mice immunized with murine Jo-1 develop a striking combination of muscle and lung inflammation that replicates features of the human anti-synthetase syndrome."
Directly supports the combined muscle/lung phenotype after Jo-1 immunization.
{ }

Source YAML

click to show 
name: Antisynthetase Syndrome
creation_date: "2026-06-29T00:00:00Z"
category: Complex
disease_term:
  preferred_term: Antisynthetase Syndrome
  term:
    id: MONDO:0019344
    label: antisynthetase syndrome
description: >-
  A systemic autoimmune disease and distinct subset of the idiopathic inflammatory
  myopathies, defined serologically by circulating autoantibodies against one of the
  cytoplasmic aminoacyl-tRNA synthetases (most commonly anti-Jo-1 / anti-histidyl-tRNA
  synthetase; also anti-PL-7, anti-PL-12, anti-EJ, anti-OJ, anti-KS). It is dominated by a
  constellation of interstitial lung disease (often the prognosis-determining feature),
  inflammatory myositis, and inflammatory (usually non-erosive) arthritis, frequently
  accompanied by mechanic's hands, Raynaud phenomenon, and unexplained fever. The
  ILD-predominant, antibody-defined phenotype distinguishes it from classic polymyositis
  and dermatomyositis. It is multifactorial/autoimmune (HLA-associated), not Mendelian.
synonyms:
- Anti-synthetase syndrome
- Anti-aminoacyl-tRNA synthetase syndrome
- Anti-Jo-1 syndrome
- ASyS
- ASSD
parents:
- Autoimmune Disease
- Inflammatory Myopathy
pathophysiology:
- name: Loss of Tolerance to Aminoacyl-tRNA Synthetases
  description: >-
    The defining upstream event is breakdown of immune tolerance to one of the cytoplasmic
    aminoacyl-tRNA synthetase (aaRS) enzymes, generating circulating anti-aaRS
    autoantibodies. These antibodies are defining biomarkers and plausible mechanistic
    participants, but their precise pathogenic contribution is not yet established. The
    aaRS enzymes are housekeeping enzymes whose native role is tRNA aminoacylation.
  role: trigger
  mechanism_confidence: PROVISIONAL
  biological_scale: MOLECULAR
  genes:
  - preferred_term: HLA-DRB1
    term:
      id: hgnc:4948
      label: HLA-DRB1
  - preferred_term: HARS1
    term:
      id: hgnc:4816
      label: HARS1
  - preferred_term: TARS1
    term:
      id: hgnc:11572
      label: TARS1
  - preferred_term: AARS1
    term:
      id: hgnc:20
      label: AARS1
  - preferred_term: GARS1
    term:
      id: hgnc:4162
      label: GARS1
  - preferred_term: IARS1
    term:
      id: hgnc:5330
      label: IARS1
  - preferred_term: NARS1
    term:
      id: hgnc:7643
      label: NARS1
  molecular_functions:
  - preferred_term: Aminoacyl-tRNA ligase activity (autoantigen native function)
    term:
      id: GO:0004812
      label: aminoacyl-tRNA ligase activity
  evidence:
  - reference: PMID:36280495
    reference_title: "Mechanistic perspectives on anti-aminoacyl-tRNA synthetase syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Antisynthetase syndrome (ASSD) is an autoimmune disease characterized by circulating
      autoantibodies against one of eight aminoacyl-tRNA synthetases
    explanation: >-
      Establishes that the disease is defined by autoantibodies against the aaRS enzymes,
      the serological hallmark and upstream immune lesion.
  downstream:
  - target: Tissue-Specific Secretion of Aminoacyl-tRNA Synthetases
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:36280495
      reference_title: "Mechanistic perspectives on anti-aminoacyl-tRNA synthetase syndrome."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "we propose that ASSD pathogenesis involves the tissue-specific secretion of aaRSs"
      explanation: Supports a proposed, not demonstrated, disease route from loss of tolerance to extracellular aaRS exposure.
- name: Tissue-Specific Secretion of Aminoacyl-tRNA Synthetases
  description: >-
    Damaged or regenerating muscle and inflamed lung secrete certain aaRS enzymes
    extracellularly; this tissue-specific secretion is proposed as a key determinant of
    which aaRS becomes an autoantigen, exposing the enzyme to the immune system outside its
    normal cytoplasmic compartment.
  mechanism_confidence: HYPOTHETICAL
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: Skeletal muscle cell
    term:
      id: CL:0000188
      label: cell of skeletal muscle
  - preferred_term: Alveolar macrophage
    term:
      id: CL:0000583
      label: alveolar macrophage
  molecular_functions:
  - preferred_term: Aminoacyl-tRNA ligase activity (secreted autoantigen)
    term:
      id: GO:0004812
      label: aminoacyl-tRNA ligase activity
  evidence:
  - reference: PMID:36280495
    reference_title: "Mechanistic perspectives on anti-aminoacyl-tRNA synthetase syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      we propose that ASSD pathogenesis involves the tissue-specific secretion of aaRSs
    explanation: >-
      Supports extracellular, tissue-specific secretion of aaRS enzymes as a proximal step
      that makes the housekeeping enzyme available as an autoantigen.
  downstream:
  - target: tRNA-Triggered Toll-Like Receptor and Interferon Amplification
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:36280495
      reference_title: "Mechanistic perspectives on anti-aminoacyl-tRNA synthetase syndrome."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        extracellular tRNAs or tRNA fragments and their ability to engage Toll-like receptor
        signaling may be important disease factors
      explanation: Supports the proposed extracellular-tRNA/TLR component but not the full secretion-to-signaling sequence.
- name: tRNA-Triggered Toll-Like Receptor and Interferon Amplification
  description: >-
    Anti-aaRS antibodies bind the synthetase together with bound tRNA or tRNA fragments,
    forming immune complexes that are internalized into endosomes where the nucleic-acid
    cargo engages Toll-like receptor signaling and drives type I interferon release - a
    self-amplifying innate-plus-adaptive loop that perpetuates autoantibody production and
    tissue inflammation.
  mechanism_confidence: HYPOTHETICAL
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: Dendritic cell
    term:
      id: CL:0000451
      label: dendritic cell
  - preferred_term: Monocyte
    term:
      id: CL:0000576
      label: monocyte
  biological_processes:
  - preferred_term: Toll-like receptor signaling pathway
    term:
      id: GO:0002224
      label: toll-like receptor signaling pathway
    modifier: INCREASED
  - preferred_term: Type I interferon production
    term:
      id: GO:0032606
      label: type I interferon production
    modifier: INCREASED
  evidence:
  - reference: PMID:36280495
    reference_title: "Mechanistic perspectives on anti-aminoacyl-tRNA synthetase syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      extracellular tRNAs or tRNA fragments and their ability to engage Toll-like receptor
      signaling may be important disease factors
    explanation: >-
      Supports tRNA-driven Toll-like receptor engagement as an innate-immune amplification
      mechanism in disease pathogenesis.
  downstream:
  - target: Autoantibody and Cytotoxic Immune Effector Production
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:36280495
      reference_title: "Mechanistic perspectives on anti-aminoacyl-tRNA synthetase syndrome."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        extracellular tRNAs or tRNA fragments and their ability to engage Toll-like receptor
        signaling may be important disease factors
      explanation: Supports innate amplification as a possible disease factor, while the downstream adaptive sequence remains unproven.
- name: Autoantibody and Cytotoxic Immune Effector Production
  description: >-
    aaRS-specific CD4+ T-cell help drives B cells and plasma cells to produce class-switched
    anti-aaRS autoantibodies, while cytotoxic effector cells are recruited; the adaptive
    response targets aaRS-expressing or aaRS-secreting tissues (lung, muscle, joint).
  mechanism_confidence: PROVISIONAL
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: CD4+ T cell
    term:
      id: CL:0000624
      label: CD4-positive, alpha-beta T cell
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  - preferred_term: Plasma cell
    term:
      id: CL:0000786
      label: plasma cell
  biological_processes:
  - preferred_term: Immunoglobulin production
    term:
      id: GO:0002377
      label: immunoglobulin production
    modifier: INCREASED
  - preferred_term: Adaptive immune response
    term:
      id: GO:0002250
      label: adaptive immune response
  evidence:
  - reference: PMID:36280495
    reference_title: "Mechanistic perspectives on anti-aminoacyl-tRNA synthetase syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      these autoantibodies are believed to play critical roles in
      ASSD pathogenesis
    explanation: >-
      Supports the central pathogenic role of the produced anti-aaRS autoantibodies in
      driving tissue-targeted disease.
  downstream:
  - target: HARS Immune-Complex Activation of Alveolar Monocyte-Macrophages
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:42121132
      reference_title: "Disparate periphery and lung immune microenvironments induced monocyte-macrophage activation as a key factor in anti-synthetase syndrome-associated interstitial lung disease."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        In vitro, human histidyl ARS-containing immune complexes (IC) induced higher expression of
        MHC-I/II, CD80/CD86, pro-inflammatory cytokines, and ARS genes in primary human
        macrophages compared with control IC.
      explanation: Directly supports macrophage activation by HARS-containing immune complexes in vitro.
  - target: Immune-Mediated Myofiber Injury
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:36280495
      reference_title: "Mechanistic perspectives on anti-aminoacyl-tRNA synthetase syndrome."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Although these autoantibodies are believed to play critical roles in
        ASSD pathogenesis, the nature of their roles remains unclear.
      explanation: Supports plausibility while explicitly leaving the autoantibody-to-myofiber causal route unresolved.
  - target: Inflammatory Arthritis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:27594777
      reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        clinical features that may include interstitial lung disease (ILD), non-erosive
        arthritis, myositis, Raynaud’s phenomenon, unexplained fever and/or mechanic’s hands
      explanation: Supports the manifestation association, not a resolved causal route from immune effectors.
  - target: Mechanic's Hands
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:27594777
      reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        clinical features that may include interstitial lung disease (ILD), non-erosive
        arthritis, myositis, Raynaud’s phenomenon, unexplained fever and/or mechanic’s hands
      explanation: Supports the manifestation association, not a resolved causal route from immune effectors.
  - target: Raynaud Phenomenon
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:27594777
      reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        clinical features that may include interstitial lung disease (ILD), non-erosive
        arthritis, myositis, Raynaud’s phenomenon, unexplained fever and/or mechanic’s hands
      explanation: Supports the manifestation association, not a resolved causal route from immune effectors.
  - target: Unexplained Fever
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:27594777
      reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        clinical features that may include interstitial lung disease (ILD), non-erosive
        arthritis, myositis, Raynaud’s phenomenon, unexplained fever and/or mechanic’s hands
      explanation: Supports the manifestation association, not a resolved causal route from immune effectors.
- name: HARS Immune-Complex Activation of Alveolar Monocyte-Macrophages
  description: >-
    In a small 2026 paired blood/BALF multi-omics study, inflammatory
    monocyte-macrophage populations were expanded in antisynthetase-syndrome ILD, and
    HARS-containing immune complexes activated primary human macrophages in vitro. This
    provides provisional, anti-Jo-1-specific support for an immune-complex-to-lung
    inflammation route; it does not establish that this mechanism explains other
    anti-synthetase specificities or clinical outcomes.
  mechanism_confidence: PROVISIONAL
  biological_scale: CELLULAR
  genes:
  - preferred_term: HARS1
    term:
      id: hgnc:4816
      label: HARS1
  cell_types:
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  biological_processes:
  - preferred_term: Macrophage activation
    term:
      id: GO:0042116
      label: macrophage activation
    modifier: INCREASED
  evidence:
  - reference: PMID:42121132
    reference_title: "Disparate periphery and lung immune microenvironments induced monocyte-macrophage activation as a key factor in anti-synthetase syndrome-associated interstitial lung disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In ASS-ILD BALF, monocyte-macrophages showed significantly higher cytokine and
      inflammatory gene module scores compared with IPF and HCs
    explanation: >-
      Supports activated alveolar monocyte-macrophage populations in the human lung;
      only four patients contributed to the single-cell analysis.
  - reference: PMID:42121132
    reference_title: "Disparate periphery and lung immune microenvironments induced monocyte-macrophage activation as a key factor in anti-synthetase syndrome-associated interstitial lung disease."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      In vitro, human histidyl ARS-containing immune complexes (IC) induced higher expression of
      MHC-I/II, CD80/CD86, pro-inflammatory cytokines, and ARS genes in primary human
      macrophages compared with control IC.
    explanation: >-
      Directly supports macrophage activation by HARS-containing immune complexes in
      vitro, without establishing in-vivo causality.
  downstream:
  - target: Immune-Mediated Alveolar Injury and Interstitial Lung Disease
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:42121132
      reference_title: "Disparate periphery and lung immune microenvironments induced monocyte-macrophage activation as a key factor in anti-synthetase syndrome-associated interstitial lung disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        monocyte-macrophage activation as a key factor in anti-synthetase
        syndrome-associated interstitial lung disease
      explanation: Supports association of activated monocyte-macrophages with ASS-ILD, not proof of the downstream causal edge.
- name: Immune-Mediated Alveolar Injury and Interstitial Lung Disease
  description: >-
    Immune effectors and interferon programs injure the alveolar interstitium, producing
    interstitial lung inflammation that can progress to fibrosis (NSIP > organizing
    pneumonia > UIP patterns). ILD frequently predominates at presentation and is the
    principal driver of morbidity and mortality.
  mechanism_confidence: PROVISIONAL
  biological_scale: TISSUE
  cell_types:
  - preferred_term: Type II pneumocyte
    term:
      id: CL:0002063
      label: pulmonary alveolar type 2 cell
  - preferred_term: Pulmonary interstitial fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  biological_processes:
  - preferred_term: Inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
    modifier: INCREASED
  evidence:
  - reference: PMID:27594777
    reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The ILD in anti-synthetase syndrome patients is often severe and rapidly progressive,
      causing much of the increased morbidity and mortality associated with anti-synthetase
      syndrome as compared to the other IIMs
    explanation: >-
      Supports interstitial lung disease as the dominant, prognosis-determining tissue
      injury in the syndrome.
  downstream:
  - target: Interstitial Lung Disease
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:27594777
      reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The ILD in anti-synthetase syndrome patients is often severe and rapidly progressive,
        causing much of the increased morbidity and mortality associated with anti-synthetase
        syndrome as compared to the other IIMs
      explanation: Directly supports clinically manifest ILD from the modeled lung-injury state.
  - target: Dyspnea
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:27594777
      reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "decreased survival was seen in patients without muscle weakness and with severe dyspnea"
      explanation: Supports dyspnea in severe disease; its attribution to ILD is clinically plausible but not tested by this excerpt.
  - target: Pulmonary Fibrosis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:27594777
      reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The most common causes of death were pulmonary fibrosis and pulmonary hypertension"
      explanation: Supports pulmonary fibrosis as a downstream severe pulmonary outcome.
  - target: Pulmonary Hypertension Secondary to ILD
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:39467037
      reference_title: "Clinical Characteristics of Anti-Synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome Project."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "secondary pulmonary hypertension due to ILD"
      explanation: Directly supports pulmonary hypertension secondary to ILD as the relevant association.
- name: Immune-Mediated Myofiber Injury
  description: >-
    Skeletal myofibers undergo immune-mediated injury with characteristic perimysial
    fragmentation, perifascicular necrosis, and aberrant sarcolemmal MHC class I
    upregulation, producing inflammatory myositis with proximal muscle weakness and
    elevated muscle enzymes.
  mechanism_confidence: PROVISIONAL
  biological_scale: TISSUE
  cell_types:
  - preferred_term: Skeletal muscle cell
    term:
      id: CL:0000188
      label: cell of skeletal muscle
  - preferred_term: CD8+ cytotoxic T cell
    term:
      id: CL:0000625
      label: CD8-positive, alpha-beta T cell
  biological_processes:
  - preferred_term: MHC class I antigen processing and presentation
    term:
      id: GO:0002474
      label: antigen processing and presentation of peptide antigen via MHC class I
    modifier: INCREASED
  evidence:
  - reference: PMID:36280495
    reference_title: "Mechanistic perspectives on anti-aminoacyl-tRNA synthetase syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Although these autoantibodies are believed to play critical roles in
      ASSD pathogenesis, the nature of their roles remains unclear.
    explanation: >-
      Supports the autoantibody-centered immune mechanism underlying tissue (including
      muscle) injury, while flagging residual mechanistic uncertainty.
  downstream:
  - target: Inflammatory Myositis
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28586844
      reference_title: "Skeletal Muscle Involvement in Antisynthetase Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "perifascicular necrosis, the characteristic finding of antisynthetase syndrome, was found in 24 patients (47%)."
      explanation: Supports tissue-level inflammatory muscle pathology in an anti-ARS-positive biopsy cohort.
  - target: Proximal Muscle Weakness
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:28586844
      reference_title: "Skeletal Muscle Involvement in Antisynthetase Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "All 51 patients presented with muscle limb weakness"
      explanation: Supports weakness as a clinical consequence in the selected muscle-biopsy cohort.
  - target: Dysphagia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:28586844
      reference_title: "Skeletal Muscle Involvement in Antisynthetase Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        All 51 patients presented with muscle limb weakness; 14 (27%) had severe limb
        weakness, 17 (33%) had neck muscle weakness, 15 (29%) had dysphagia, and 15 (29%)
        had muscle atrophy.
      explanation: Supports dysphagia in the selected anti-ARS-positive muscle-biopsy cohort.
  - target: Myalgia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:27594777
      reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        the prevalence of muscle symptoms (weakness and myalgia) was significantly lower in
        patients with anti-PL7/PL12 as compared to those with anti-Jo1
      explanation: Supports myalgia as a muscle manifestation, with antibody-specific heterogeneity.
  - target: Elevated Creatine Kinase
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:27594777
      reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Myositis activity is typically assessed via elevations in creatinine kinase (CK) and aldolase."
      explanation: Supports elevated CK as a readout of active myositis/myofiber injury.
phenotypes:
- name: Interstitial Lung Disease
  category: Respiratory
  frequency: VERY_FREQUENT
  description: >-
    The dominant organ manifestation; NSIP is the most common pattern, followed by
    organizing pneumonia and UIP. Often predominates at presentation and may be rapidly
    progressive. Prevalence ~86% in a 203-patient cohort.
  phenotype_term:
    preferred_term: Interstitial lung disease
    term:
      id: HP:0006515
      label: Interstitial pneumonitis
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:27594777
    reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In a 2013 study of 203 anti-synthetase syndrome patients, the prevalence of ILD was
      86%, more common than the prevalence of myositis (73%) or arthralgia/arthritis (60%)
    explanation: >-
      Supports both the association and a very-frequent (>80%) frequency band for ILD in
      antisynthetase syndrome.
- name: Inflammatory Myositis
  category: Musculoskeletal
  frequency: FREQUENT
  description: >-
    Inflammatory myopathy with symmetric proximal muscle weakness; may be absent or appear
    later in the disease course (notably in ILD-predominant, non-Jo-1 patients). Prevalence
    ~73% in a 203-patient cohort.
  phenotype_term:
    preferred_term: Myopathy
    term:
      id: HP:0003198
      label: Myopathy
  evidence:
  - reference: PMID:27594777
    reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In a 2013 study of 203 anti-synthetase syndrome patients, the prevalence of ILD was
      86%, more common than the prevalence of myositis (73%) or arthralgia/arthritis (60%)
    explanation: >-
      Supports the association and a frequent (30-79%) frequency band for myositis.
- name: Proximal Muscle Weakness
  category: Musculoskeletal
  description: >-
    Symmetric proximal limb weakness reflecting the inflammatory myopathy component.
  phenotype_term:
    preferred_term: Proximal muscle weakness
    term:
      id: HP:0003701
      label: Proximal muscle weakness
  evidence:
  - reference: PMID:27594777
    reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the prevalence of muscle symptoms (weakness and myalgia) was significantly lower in
      patients with anti-PL7/PL12 as compared to those with anti-Jo1
    explanation: >-
      Supports muscle weakness as a manifestation of the syndrome (more frequent in
      anti-Jo-1 disease).
- name: Inflammatory Arthritis
  category: Musculoskeletal
  frequency: FREQUENT
  description: >-
    Symmetric, usually non-erosive polyarthritis that can mimic rheumatoid arthritis;
    arthralgia/arthritis prevalence ~60% in a 203-patient cohort.
  phenotype_term:
    preferred_term: Arthritis
    term:
      id: HP:0001369
      label: Arthritis
  evidence:
  - reference: PMID:27594777
    reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In a 2013 study of 203 anti-synthetase syndrome patients, the prevalence of ILD was
      86%, more common than the prevalence of myositis (73%) or arthralgia/arthritis (60%)
    explanation: >-
      Supports the association and a frequent (30-79%) frequency band for arthralgia/arthritis.
- name: Mechanic's Hands
  category: Integumentary
  description: >-
    Hyperkeratotic, fissured, scaling skin on the radial/ulnar surfaces of the fingers;
    a characteristic but often subtle sign whose presence should prompt anti-synthetase
    antibody testing.
  phenotype_term:
    preferred_term: Mechanic's hands
    term:
      id: HP:6001013
      label: Mechanic's hands
  evidence:
  - reference: PMID:27594777
    reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the hyperkeratosis and scaling characteristic of mechanic’s hands are often subtle
      findings whose presence should prompt further testing for anti-synthetase antibodies
    explanation: >-
      Supports mechanic's hands (finger hyperkeratosis/scaling) as a characteristic
      cutaneous feature of the syndrome.
- name: Raynaud Phenomenon
  category: Vascular
  description: >-
    Episodic digital vasospasm; a connective-tissue-disease-associated feature commonly
    seen in antisynthetase syndrome.
  phenotype_term:
    preferred_term: Raynaud phenomenon
    term:
      id: HP:0030880
      label: Raynaud phenomenon
  evidence:
  - reference: PMID:27594777
    reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      clinical features that may include interstitial lung disease (ILD), non-erosive
      arthritis, myositis, Raynaud’s phenomenon, unexplained fever and/or mechanic’s hands
    explanation: >-
      Supports Raynaud phenomenon as a recognized clinical feature of the syndrome.
- name: Unexplained Fever
  category: Constitutional
  description: >-
    Unexplained fever, often accompanying disease flares, is part of the antisynthetase
    constellation.
  phenotype_term:
    preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
  evidence:
  - reference: PMID:27594777
    reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      clinical features that may include interstitial lung disease (ILD), non-erosive
      arthritis, myositis, Raynaud’s phenomenon, unexplained fever and/or mechanic’s hands
    explanation: >-
      Supports unexplained fever as a recognized clinical feature of the syndrome.
- name: Dyspnea
  category: Respiratory
  description: >-
    Exertional breathlessness from interstitial lung disease, frequently the presenting
    symptom in ILD-predominant disease.
  phenotype_term:
    preferred_term: Dyspnea
    term:
      id: HP:0002094
      label: Dyspnea
  evidence:
  - reference: PMID:27594777
    reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      decreased survival was seen in patients without muscle weakness and with severe dyspnea
    explanation: >-
      Supports dyspnea (from ILD) as a clinically important manifestation associated with
      worse survival.
- name: Pulmonary Fibrosis
  category: Respiratory
  description: >-
    Fibrotic progression of the interstitial lung disease (e.g., fibrotic NSIP or UIP
    pattern), a leading cause of death.
  phenotype_term:
    preferred_term: Pulmonary fibrosis
    term:
      id: HP:0002206
      label: Pulmonary fibrosis
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:27594777
    reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most common causes of death were pulmonary fibrosis and pulmonary hypertension
    explanation: >-
      Supports pulmonary fibrosis as a fibrotic ILD outcome and a leading cause of death in
      the syndrome.
- name: Pulmonary Hypertension Secondary to ILD
  category: Cardiovascular
  description: >-
    Pulmonary hypertension can complicate chronic interstitial lung disease and is
    associated with poor prognosis. It should not be conflated with pulmonary arterial
    hypertension, which did not distinguish cases from mimics in the CLASS cohort.
  review_notes: >-
    No HPO term is bound because the available disease-specific evidence supports
    secondary pulmonary hypertension due to ILD, not the narrower pulmonary arterial
    hypertension term HP:0002092.
  evidence:
  - reference: PMID:39467037
    reference_title: "Clinical Characteristics of Anti-Synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome Project."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Specific variables associated with ASSD included arthritis, diffuse myalgia,
      muscle weakness, muscle enzyme elevation, ILD, mechanic's hands, secondary
      pulmonary hypertension due to ILD, Raynaud phenomenon, and unexplained fever.
    explanation: >-
      Supports secondary pulmonary hypertension due to ILD in a large international
      case-control classification cohort.
- name: Dysphagia
  category: Gastrointestinal
  description: >-
    Swallowing difficulty from striated pharyngeal/esophageal muscle involvement in the
    myositis component.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:28586844
    reference_title: "Skeletal Muscle Involvement in Antisynthetase Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All 51 patients presented with muscle limb weakness; 14 (27%) had severe limb
      weakness, 17 (33%) had neck muscle weakness, 15 (29%) had dysphagia, and 15 (29%)
      had muscle atrophy.
    explanation: >-
      Supports dysphagia in a selected anti-ARS-positive muscle-biopsy cohort; the 29%
      estimate is not generalized to all antisynthetase syndrome.
- name: Myalgia
  category: Musculoskeletal
  description: >-
    Muscle pain accompanying the inflammatory myopathy.
  phenotype_term:
    preferred_term: Myalgia
    term:
      id: HP:0003326
      label: Myalgia
  evidence:
  - reference: PMID:27594777
    reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the prevalence of muscle symptoms (weakness and myalgia) was significantly lower in
      patients with anti-PL7/PL12 as compared to those with anti-Jo1
    explanation: >-
      Supports myalgia as a muscle symptom of the syndrome.
- name: Elevated Creatine Kinase
  category: Laboratory
  description: >-
    Elevated serum creatine kinase reflecting myofiber injury; present when myositis is
    active, but may be normal in amyopathic/ILD-predominant disease.
  phenotype_term:
    preferred_term: Elevated circulating creatine kinase concentration
    term:
      id: HP:0003236
      label: Elevated circulating creatine kinase concentration
  evidence:
  - reference: PMID:27594777
    reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      presence should prompt further testing for anti-synthetase antibodies and elevated
      muscle enzymes
    explanation: >-
      Supports elevated muscle enzymes (creatine kinase) as a laboratory feature prompted by
      the syndrome's findings.
  reports_on:
  - target: Immune-Mediated Myofiber Injury
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Serum creatine kinase reflects immune-mediated myofiber injury/necrosis.
    evidence:
    - reference: PMID:27594777
      reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Myositis activity is typically assessed via elevations in creatinine kinase (CK) and aldolase."
      explanation: Supports CK as a positive clinical readout of myositis activity.
biochemical:
- name: Anti-Jo-1 (Anti-Histidyl-tRNA Synthetase) Autoantibody
  presence: Elevated
  context: >-
    The most common anti-aminoacyl-tRNA synthetase antibody; defines the classic, more
    myositis-predominant phenotype. Antibody titer correlates with disease activity.
  evidence:
  - reference: PMID:28339994
    reference_title: "A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One hundred and twenty-four (73.4%) patients were positive for
      anti-Jo1
    explanation: >-
      Supports anti-Jo-1 as the most frequent anti-synthetase antibody in an
      antisynthetase-syndrome cohort.
- name: Anti-PL-7 / Anti-PL-12 (and other non-Jo-1 anti-ARS) Autoantibodies
  presence: Elevated
  context: >-
    Non-Jo-1 anti-aminoacyl-tRNA synthetase antibodies (anti-PL-7/TARS1, anti-PL-12/AARS1,
    anti-EJ/GARS1, anti-OJ/IARS1, anti-KS/NARS1) are associated with more lung-predominant,
    often amyopathic disease.
  evidence:
  - reference: PMID:22771754
    reference_title: "Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      ILD was more frequent (80% and 88% vs 67%, p=0.014)
      whereas myositis was less common (44% and 47% vs 74%, p<0.001) in patients with
      anti-PL7 and anti-PL12 compared to anti-Jo1
    explanation: >-
      Supports the lung-predominant, less-myopathic phenotype of anti-PL-7/anti-PL-12
      versus anti-Jo-1.
- name: Anti-Ro52 (TRIM21) Co-Antibody
  presence: Elevated
  context: >-
    Frequently co-positive with anti-synthetase antibodies; in one cohort it was more
    prevalent in anti-Jo-1-positive disease and linked to earlier mechanic's hands,
    DM-specific skin findings, and arthritis.
  evidence:
  - reference: PMID:28339994
    reference_title: "A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Concurrent anti-Ro52 was more prevalent in anti-Jo1 patients
      and was associated with earlier development of mechanic's hands, DM-specific
      skin findings and arthritis
    explanation: >-
      Supports anti-Ro52 co-positivity as a phenotype-modifying serology.
genetic:
- name: HLA-DRB1 (8.1 ancestral haplotype) susceptibility
  gene_term:
    preferred_term: HLA-DRB1
    term:
      id: hgnc:4948
      label: HLA-DRB1
  association: Risk Factor
  relationship_type: SUSCEPTIBILITY
  notes: >-
    MHC class II is the strongest susceptibility locus; HLA-DRB1*03:01 (and the linked 8.1
    ancestral haplotype including HLA-B*08:01) is the principal predisposing marker,
    particularly for anti-Jo-1, while HLA-DRB1*07:01 appears protective. This is a
    susceptibility association, not a Mendelian causal mutation.
  evidence:
  - reference: PMID:33301929
    reference_title: "HLA association with the susceptibility to anti-synthetase syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A statistically significant increase of HLA-DRB1*03:01 and HLA-B*08:01
      alleles in patients with ASSD compared to healthy controls was disclosed
    explanation: >-
      Directly supports HLA-DRB1*03:01 (and linked HLA-B*08:01 of the 8.1 haplotype) as a
      susceptibility allele for antisynthetase syndrome.
  - reference: PMID:33301929
    reference_title: "HLA association with the susceptibility to anti-synthetase syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a statistically significant increase of
      HLA-DRB1*03:01 allele in anti-Jo-1 positive compared to anti-Jo-1 negative
      patients with ASSD was observed
    explanation: >-
      Supports the particularly strong HLA-DRB1*03:01 association with anti-Jo-1-positive
      disease.
- name: HARS1 (autoantigen; anti-Jo-1 target)
  gene_term:
    preferred_term: HARS1
    term:
      id: hgnc:4816
      label: HARS1
  association: Autoantigen
  notes: >-
    Histidyl-tRNA synthetase (HisRS) is the target of anti-Jo-1, the most common
    anti-synthetase antibody. HARS1 is the autoantigen, not a mutated disease gene.
  evidence:
  - reference: PMID:35634293
    reference_title: "Aminoacyl-tRNA Synthetases: On Anti-Synthetase Syndrome and Beyond."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Histidyl-tRNA Class II HisRS Jo-1 HARS"
    explanation: >-
      The review's autoantigen table maps histidyl-tRNA synthetase/HARS to anti-Jo-1.
- name: TARS1 (autoantigen; anti-PL-7 target)
  gene_term:
    preferred_term: TARS1
    term:
      id: hgnc:11572
      label: TARS1
  association: Autoantigen
  notes: Threonyl-tRNA synthetase; target of anti-PL-7. Autoantigen, not a causal mutation.
  evidence:
  - reference: PMID:35634293
    reference_title: "Aminoacyl-tRNA Synthetases: On Anti-Synthetase Syndrome and Beyond."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Threonyl-tRNA Class II ThrRS PL-7 TARS"
    explanation: >-
      The review's autoantigen table maps threonyl-tRNA synthetase/TARS to anti-PL-7.
- name: AARS1 (autoantigen; anti-PL-12 target)
  gene_term:
    preferred_term: AARS1
    term:
      id: hgnc:20
      label: AARS1
  association: Autoantigen
  notes: Alanyl-tRNA synthetase; target of anti-PL-12. Autoantigen, not a causal mutation.
  evidence:
  - reference: PMID:35634293
    reference_title: "Aminoacyl-tRNA Synthetases: On Anti-Synthetase Syndrome and Beyond."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Alanyl-tRNA Class II AlaRS PL-12 AARS"
    explanation: >-
      The review's autoantigen table maps alanyl-tRNA synthetase/AARS to anti-PL-12.
- name: GARS1 (autoantigen; anti-EJ target)
  gene_term:
    preferred_term: GARS1
    term:
      id: hgnc:4162
      label: GARS1
  association: Autoantigen
  notes: Glycyl-tRNA synthetase; target of anti-EJ. Autoantigen, not a causal mutation.
  evidence:
  - reference: PMID:35634293
    reference_title: "Aminoacyl-tRNA Synthetases: On Anti-Synthetase Syndrome and Beyond."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Glycyl-tRNA Class II GlyRS EJ GARS"
    explanation: >-
      The review's autoantigen table maps glycyl-tRNA synthetase/GARS to anti-EJ.
- name: IARS1 (autoantigen; anti-OJ target)
  gene_term:
    preferred_term: IARS1
    term:
      id: hgnc:5330
      label: IARS1
  association: Autoantigen
  notes: Isoleucyl-tRNA synthetase; target of anti-OJ. Autoantigen, not a causal mutation.
  evidence:
  - reference: PMID:35634293
    reference_title: "Aminoacyl-tRNA Synthetases: On Anti-Synthetase Syndrome and Beyond."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Isoleucyl-tRNA Class II IleRS OJ IARS"
    explanation: >-
      The review's autoantigen table maps isoleucyl-tRNA synthetase/IARS to anti-OJ.
- name: NARS1 (autoantigen; anti-KS target)
  gene_term:
    preferred_term: NARS1
    term:
      id: hgnc:7643
      label: NARS1
  association: Autoantigen
  notes: Asparaginyl-tRNA synthetase; target of anti-KS. Autoantigen, not a causal mutation.
  evidence:
  - reference: PMID:35634293
    reference_title: "Aminoacyl-tRNA Synthetases: On Anti-Synthetase Syndrome and Beyond."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Asparaginyl-tRNA Class II AsnRS KS NARS"
    explanation: >-
      The review's autoantigen table maps asparaginyl-tRNA synthetase/NARS to anti-KS.
- name: TRIM21 (autoantigen; anti-Ro52 target)
  gene_term:
    preferred_term: TRIM21
    term:
      id: hgnc:11312
      label: TRIM21
  association: Autoantigen
  relationship_type: BIOMARKER
  notes: >-
    Ro52/TRIM21 is the target of a phenotype-associated co-antibody; it is modeled as a
    biomarker rather than a causal disease gene.
  evidence:
  - reference: PMID:28339994
    reference_title: "A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Concurrent anti-Ro52 was more prevalent in anti-Jo1 patients
      and was associated with earlier development of mechanic's hands, DM-specific
      skin findings and arthritis
    explanation: >-
      Supports TRIM21/Ro52 as a co-autoantigen biomarker associated with phenotype, not
      as a causal disease gene.
inheritance:
- name: Not Mendelian (multifactorial autoimmune)
  description: >-
    Antisynthetase syndrome is not inherited in a Mendelian fashion; it is a multifactorial,
    polygenic autoimmune disease with HLA-driven susceptibility (e.g., HLA-DRB1*03:01).
    Penetrance, expressivity, anticipation, and carrier-frequency concepts do not apply.
  evidence:
  - reference: PMID:33301929
    reference_title: "HLA association with the susceptibility to anti-synthetase syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A statistically significant increase of HLA-DRB1*03:01 and HLA-B*08:01
      alleles in patients with ASSD compared to healthy controls was disclosed
    explanation: >-
      Supports HLA susceptibility rather than a Mendelian inheritance model; the excerpt
      does not by itself prove the absence of rare familial aggregation.
treatments:
- name: Corticosteroids
  description: >-
    First-line therapy for active muscle and/or lung disease. Corticosteroid monotherapy is
    frequently insufficient (lung disease recurs with tapering), so adjunctive
    immunosuppression is usually added.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: prednisone
      term:
        id: CHEBI:8382
        label: prednisone
    - preferred_term: prednisolone
      term:
        id: CHEBI:8378
        label: prednisolone
  target_mechanisms:
  - target: Immune-Mediated Alveolar Injury and Interstitial Lung Disease
    description: Broad anti-inflammatory/immunosuppressive control of the alveolar inflammation.
    evidence:
    - reference: PMID:38973731
      reference_title: "2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        glucocorticoids are conditionally recommended for first-line ILD treatment in
        all other SARDs.
      explanation: Supports targeting SARD-ILD clinically, not the detailed molecular mechanism.
  evidence:
  - reference: PMID:27594777
    reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Corticosteroids have long been first-line in the treatment of IIMs, though when
      corticosteroids are used as monotherapy in anti-synthetase syndrome, there is frequent
      lung disease recurrence with corticosteroid tapering
    explanation: >-
      Supports corticosteroids as first-line and the rationale for adding steroid-sparing
      agents.
  - reference: PMID:38973731
    reference_title: "2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      glucocorticoids are conditionally recommended for first-line ILD treatment in
      all other SARDs.
    explanation: >-
      Provides an authoritative conditional recommendation for glucocorticoids in
      non-systemic-sclerosis SARD-ILD; it is not specific to antisynthetase syndrome.
- name: Mycophenolate Mofetil
  description: >-
    A frequently used adjunctive steroid-sparing immunosuppressant; inhibits proliferating
    lymphocytes by altering purine synthesis. Often combined with prednisone for ILD.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: mycophenolate mofetil
      term:
        id: CHEBI:8764
        label: mycophenolate mofetil
  target_mechanisms:
  - target: Autoantibody and Cytotoxic Immune Effector Production
    description: Suppresses proliferating lymphocytes driving the autoimmune effector response.
    evidence:
    - reference: PMID:27594777
      reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Frequently used adjunctive agents include azathioprine, mycophenolate mofetil, tacrolimus, rituximab, and cyclophosphamide"
      explanation: Supports clinical use of mycophenolate as immunosuppression, not this molecular target assignment directly.
  evidence:
  - reference: PMID:27594777
    reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Frequently used adjunctive agents include
      azathioprine, mycophenolate mofetil, tacrolimus, rituximab, and cyclophosphamide
    explanation: >-
      Supports mycophenolate mofetil as a frequently used adjunctive immunosuppressant.
- name: Azathioprine
  description: >-
    Adjunctive steroid-sparing immunosuppressant; halts purine synthesis. Most frequently
    used as maintenance therapy in conjunction with prednisone.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: azathioprine
      term:
        id: CHEBI:2948
        label: azathioprine
  evidence:
  - reference: PMID:27594777
    reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      azathioprine has been most frequently used as maintenance therapy often in conjunction
      with prednisone
    explanation: >-
      Supports azathioprine as a maintenance steroid-sparing agent.
- name: Tacrolimus
  description: >-
    Calcineurin inhibitor used as add-on therapy, particularly for more severe ILD; case
    series in antisynthetase-syndrome-ILD show improved lung function and reduced
    corticosteroid dose.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: tacrolimus
      term:
        id: CHEBI:61049
        label: tacrolimus (anhydrous)
  target_mechanisms:
  - target: Autoantibody and Cytotoxic Immune Effector Production
    description: Calcineurin inhibition suppresses T-cell-driven autoimmune effector activity.
    evidence:
    - reference: PMID:27594777
      reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        A 2005 case series specifically studied tacrolimus efficacy in 15 patients with
        anti-synthetase syndrome-ILD.
      explanation: Supports clinical use in the disease but not the mechanistic target assignment directly.
  evidence:
  - reference: PMID:27594777
    reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A 2005 case series specifically studied tacrolimus efficacy in 15 patients with
      anti-synthetase syndrome-ILD. Most of these patients had Jo-1 autoantibodies, and
      experienced improvement in lung function and muscle symptoms
    explanation: >-
      Supports tacrolimus as an effective add-on for antisynthetase-syndrome-ILD.
- name: Rituximab
  description: >-
    Anti-CD20 monoclonal antibody depleting B cells; used for severe, progressive, or
    refractory ILD ("rescue therapy"), with case series showing FVC improvement.
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: rituximab
      term:
        id: NCIT:C1702
        label: Rituximab
  target_mechanisms:
  - target: Autoantibody and Cytotoxic Immune Effector Production
    description: B-cell depletion reduces autoantibody-producing plasma-cell precursors.
    evidence:
    - reference: PMID:27594777
      reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In the setting of anti-synthetase syndrome, we use rituximab for patients with severe progressive and/or refractory ILD"
      explanation: Supports disease use of a B-cell-directed agent, not direct measurement of the modeled mechanism.
  evidence:
  - reference: PMID:27594777
    reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In the setting of anti-synthetase syndrome, we use rituximab for patients with severe
      progressive and/or refractory ILD
    explanation: >-
      Supports rituximab for severe progressive/refractory antisynthetase-syndrome ILD.
  - reference: PMID:39083028
    reference_title: "Management and outcomes of interstitial lung disease associated with anti-synthetase syndrome: a systematic literature review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Patients receiving rituximab had 12.2% improvement in FVC and 2.9%
      increase in DLco at 1 year; for patients receiving CYC, there was 17%
      improvement and 6.3% increase, respectively.
    explanation: >-
      Summarizes observed pulmonary-function improvement, while the review found no
      conclusive comparative treatment difference and called for robust trials.
- name: Cyclophosphamide
  description: >-
    Cytotoxic alkylating agent reserved for severe IIM-ILD, particularly acute
    respiratory distress syndrome / rapidly progressive ILD, given its toxicity profile.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: cyclophosphamide
      term:
        id: CHEBI:4027
        label: cyclophosphamide
  evidence:
  - reference: PMID:27594777
    reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      have used cyclophosphamide in ARDS
    explanation: >-
      Supports cyclophosphamide reserved for severe/ARDS-like antisynthetase-syndrome ILD.
  - reference: PMID:39083028
    reference_title: "Management and outcomes of interstitial lung disease associated with anti-synthetase syndrome: a systematic literature review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Patients receiving rituximab had 12.2% improvement in FVC and 2.9%
      increase in DLco at 1 year; for patients receiving CYC, there was 17%
      improvement and 6.3% increase, respectively.
    explanation: >-
      Summarizes observed cyclophosphamide-associated pulmonary-function improvement;
      heterogeneous non-randomized evidence does not establish comparative superiority.
- name: Intravenous Immunoglobulin (IVIG)
  description: >-
    Pooled donor IgG used as adjunctive therapy, especially for refractory myositis; a case
    report suggests possible benefit in IIM-related ILD.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:27594777
    reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A recent case report suggested IVIG may be effective in ILD related to IIM as well
    explanation: >-
      Supports only case-report-level possible benefit in IIM-related ILD, not established
      antisynthetase-syndrome efficacy or the refractory-myositis qualifier.
- name: Lung Transplantation
  description: >-
    Reserved for end-stage progressive interstitial lung disease refractory to medical
    therapy.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: organ transplantation
    term:
      id: NCIT:C15289
      label: Organ Transplantation
  evidence:
  - reference: PMID:27594777
    reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      progressive interstitial lung disease necessitating lung transplantation
    explanation: >-
      Supports lung transplantation for end-stage progressive ILD.
diagnosis:
- name: Anti-Aminoacyl-tRNA Synthetase Antibody Testing
  description: >-
    The serological cornerstone of diagnosis. Connors (2010) and Solomon (2011) proposed
    historical classification frameworks combining an anti-tRNA-synthetase autoantibody
    with compatible clinical features. They should not be represented as universally
    accepted diagnostic criteria; the international CLASS project is developing
    data-driven classification criteria.
  evidence:
  - reference: PMID:27594777
    reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These criteria proposed that all patients with anti-synthetase syndrome must have
      evidence for a tRNA synthetase autoantibody, in addition to one or more of the
      following clinical features: mechanic’s hands, Raynaud’s phenomenon, myositis, ILD,
      arthritis, and/or unexplained fever
    explanation: >-
      Supports the components of the historical Connors proposal, not universal validation.
  - reference: PMID:39467037
    reference_title: "Clinical Characteristics of Anti-Synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome Project."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Anti-synthetase syndrome (ASSD) is a rare systemic autoimmune
      rheumatic disease (SARD) with significant heterogeneity and no shared
      classification criteria.
    explanation: >-
      Establishes the current lack of shared validated classification criteria and the
      purpose of the international CLASS effort.
- name: High-Resolution Chest CT and Pulmonary Function Testing
  description: >-
    HRCT characterizes the ILD pattern (NSIP/OP/UIP); pulmonary function tests with DLCO
    assess restriction and diffusion and are used for serial monitoring.
  evidence:
  - reference: PMID:27594777
    reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Diagnosis is made by a multidisciplinary
      approach, synthesizing rheumatology and pulmonary evaluations, along with
      serologic, radiographic, and occasionally muscle and/or lung biopsy results
    explanation: >-
      Supports the multidisciplinary, serologic/radiographic/biopsy-based diagnostic workup.
differential_diagnoses:
- name: Polymyositis and Dermatomyositis
  description: >-
    Other idiopathic inflammatory myopathies with which antisynthetase syndrome overlaps;
    historically these patients were diagnosed as PM or DM.
  distinguishing_features:
  - >-
    Antisynthetase syndrome is defined by anti-aminoacyl-tRNA synthetase antibodies and has
    a higher prevalence and severity of ILD than DM/PM.
  - >-
    It lacks the defining DM skin signs (heliotrope rash, Gottron papules) unless in overlap.
  - >-
    Muscle biopsy shows perimysial fragmentation/perifascicular necrosis distinct from DM
    perifascicular atrophy and PM endomysial CD8 invasion.
  evidence:
  - reference: PMID:27594777
    reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There is a higher prevalence and increased severity
      of interstitial lung disease in patients with anti-synthetase syndrome, as
      compared to dermatomyositis and polymyositis
    explanation: >-
      Supports the ILD-predominance distinction from DM/PM.
- name: Idiopathic Interstitial Pneumonia (e.g., IPF / idiopathic NSIP)
  description: >-
    Antisynthetase-syndrome ILD can present as apparently idiopathic interstitial pneumonia
    before the autoimmune basis is recognized.
  distinguishing_features:
  - >-
    A myositis-antibody panel reveals an anti-synthetase antibody; in one retrospective
    analysis of 198 idiopathic interstitial pneumonia patients, 13 were later found to have
    an anti-synthetase antibody.
  evidence:
  - reference: PMID:27594777
    reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      in a recent retrospective analysis of 198 patients with idiopathic interstitial
      pneumonia, 13 patients were later noted to have an anti-synthetase antibody
    explanation: >-
      Supports the need to differentiate antisynthetase ILD from idiopathic interstitial
      pneumonia by antibody testing.
epidemiology:
- name: Incidence and Prevalence
  description: >-
    A rare disease. In a US population-based cohort (Olmsted County, Minnesota, 1998-2019),
    the age- and sex-adjusted incidence was 0.56 per 100,000 and point prevalence 9.21 per
    100,000. No significant increase in malignancy risk was observed in this and another
    cohort.
  evidence:
  - reference: PMID:39814448
    reference_title: "Epidemiology of Antisynthetase Syndrome and Risk of Malignancy in a Population-Based Cohort (1998-2019)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The age- and sex-adjusted
      incidence of ASS was 0.56 (95% CI 0.25-0.87) per 100,000 population.
    explanation: Supports the population-based incidence estimate.
  - reference: PMID:28339994
    reference_title: "A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There was no
      significant increase in mortality or cancer risk in ASyS patients compared with
      the general US population.
    explanation: >-
      Supports the comparatively low malignancy/mortality risk relative to classic
      dermatomyositis.
progression:
- phase: Accrual of Manifestations and ILD-Driven Course
  notes: >-
    Adult-onset (peak 5th-6th decade), subacute-to-chronic and insidious; manifestations
    accrue over time from "incomplete" to "complete" syndrome. Course is chronic and
    relapsing, with ILD severity (especially fibrotic progression) determining prognosis.
    Phenotype and survival correlate with anti-ARS antibody specificity (worse with
    anti-PL-7/PL-12 than anti-Jo-1).
  evidence:
  - reference: PMID:22771754
    reference_title: "Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In patients with ASS, the phenotype and the
      survival were correlated with the anti-ARS specificity.
    explanation: >-
      Supports antibody-specificity-dependent phenotype and survival.
  - reference: PMID:41376133
    reference_title: "Clinical profiles associated with rapidly progressive interstitial lung disease in antisynthetase syndrome: A multicentric cohort study (TYPASS study)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In our study, 39% of patients had RP-ILD at ILD diagnosis.
    explanation: >-
      Supports a clinically important rapidly progressive ILD subgroup in a 132-patient
      multicenter ASyS-ILD cohort; it is not an all-ASyS frequency estimate.
animal_models:
- species: Mus musculus
  genotype: Wild-type C57BL/6 and NOD congenic mice immunized with murine Jo-1 protein
  description: >-
    Immunization with murine histidyl-tRNA synthetase generated Jo-1-specific adaptive
    immunity and combined muscle and lung inflammation. The inducible, anti-Jo-1-specific
    model supports antigen-directed pathogenicity but does not reproduce chronic human
    multisystem disease or non-Jo-1 subtypes.
  genes:
  - preferred_term: Hars1
    term:
      id: hgnc:4816
      label: HARS1
  associated_phenotypes:
  - Inflammatory Myositis
  - Interstitial Lung Disease
  evidence:
  - reference: PMID:17826948
    reference_title: "Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      mice immunized with murine Jo-1 develop a
      striking combination of muscle and lung inflammation that replicates features of
      the human anti-synthetase syndrome.
    explanation: >-
      Directly supports the combined muscle/lung phenotype after Jo-1 immunization.
clinical_trials:
- name: NCT03770663
  phase: PHASE_III
  status: UNKNOWN
  description: >-
    CATR.PAT is a registered 52-week randomized, controlled, open-label comparison of
    cyclophosphamide followed by azathioprine versus tacrolimus for first-line or relapsing
    antisynthetase-syndrome ILD. As of the 2026-08-05 audit, the registry status is unknown
    and no results are represented here; registration is not evidence of efficacy.
  target_phenotypes:
  - preferred_term: Interstitial lung disease
    term:
      id: HP:0006515
      label: Interstitial pneumonitis
  evidence:
  - reference: clinicaltrials:NCT03770663
    reference_title: "Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung Disease : Multicentric Randomized Phase III Trial"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CATR.PAT study is a 52 weeks, randomized, comparative, controlled, open-labeled,
      phase III, therapeutic clinical trial, comparing two treatment strategies.
    explanation: >-
      Supports the registered design and comparison, not completion or treatment effect.
- name: NCT01276470
  phase: NOT_APPLICABLE
  status: RECRUITING
  description: >-
    Observational case-control research comparing pre-onset infectious and noninfectious
    environmental exposures among people with myositis with antisynthetase antibodies,
    other myositis, and healthy volunteers. The current registry listed recruiting at the
    2026-08-05 audit; no causal exposure result is asserted.
  evidence:
  - reference: clinicaltrials:NCT01276470
    reference_title: "Environmental Risk Factors for the Anti-Synthetase Syndrome"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      To determine whether selected infectious and noninfectious environmental exposures are more common in individuals who have myositis with the anti-synthetase syndrome, compared with healthy volunteers.
    explanation: >-
      Supports the observational study objective, not any environmental causal claim.
discussions:
- discussion_id: asys_autoantibody_pathogenicity
  prompt: >-
    Which anti-aaRS antibodies are directly pathogenic in vivo, and through which
    antigen-, cell-, and organ-specific routes?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Loss of Tolerance to Aminoacyl-tRNA Synthetases
  - pathophysiology#tRNA-Triggered Toll-Like Receptor and Interferon Amplification
  - pathophysiology#HARS Immune-Complex Activation of Alveolar Monocyte-Macrophages
  rationale: >-
    Reviews describe the antibody roles as unclear. The 2026 human multi-omics and in-vitro
    study strengthens a HARS immune-complex/macrophage route but is small and does not
    establish in-vivo causality or generalization across anti-aaRS specificities.
  evidence:
  - reference: PMID:36280495
    reference_title: "Mechanistic perspectives on anti-aminoacyl-tRNA synthetase syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Although these autoantibodies are believed to play critical roles in
      ASSD pathogenesis, the nature of their roles remains unclear.
    explanation: The mechanistic review explicitly identifies the unresolved pathogenic role.
- discussion_id: asys_treatment_comparative_evidence
  prompt: >-
    Which immunosuppressive strategy provides the best benefit-risk profile for initial,
    progressive, and rapidly progressive antisynthetase-syndrome ILD?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - treatments#Rituximab
  - treatments#Cyclophosphamide
  - treatments#Tacrolimus
  rationale: >-
    Available outcome evidence is dominated by retrospective series and heterogeneous
    regimens. The registered CATR.PAT randomized comparison has unknown registry status
    and no represented results, so comparative efficacy remains unresolved.
  evidence:
  - reference: PMID:39083028
    reference_title: "Management and outcomes of interstitial lung disease associated with anti-synthetase syndrome: a systematic literature review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      found no conclusive difference between effectiveness of treatments. More robust
      trials are required to reduce morbidity and mortality resulting from ASS-ILD.
    explanation: The systematic review states the comparative-evidence limitation directly.
- discussion_id: asys_classification_criteria
  prompt: >-
    Which combination of serology and manifestations will yield validated, generalizable
    antisynthetase-syndrome classification criteria?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - diagnosis#Anti-Aminoacyl-tRNA Synthetase Antibody Testing
  rationale: >-
    Connors and Solomon are historical proposals. The large international CLASS project
    has identified discriminating variables, but the cited publication does not present
    completed validated criteria.
  evidence:
  - reference: PMID:39467037
    reference_title: "Clinical Characteristics of Anti-Synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome Project."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Anti-synthetase syndrome (ASSD) is a rare systemic autoimmune
      rheumatic disease (SARD) with significant heterogeneity and no shared
      classification criteria.
    explanation: Directly supports the open classification-criteria gap.
classifications:
  harrisons_chapter:
  - classification_value: IMMUNE_RHEUMATOLOGIC
    evidence:
    - reference: PMID:27594777
      reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Anti-synthetase syndrome is an autoimmune condition, characterized by antibodies
        directed against an aminoacycl transfer RNA synthetase
      explanation: >-
        Supports classification as a systemic autoimmune/rheumatologic disease.
references:
- reference: PMID:36280495
  title: "Mechanistic perspectives on anti-aminoacyl-tRNA synthetase syndrome."
  findings: []
- reference: PMID:27594777
  title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
  findings: []
- reference: PMID:39814448
  title: "Epidemiology of Antisynthetase Syndrome and Risk of Malignancy in a Population-Based Cohort (1998-2019)."
  findings: []
- reference: PMID:22771754
  title: "Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity."
  findings: []
- reference: PMID:28339994
  title: "A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies."
  findings: []
- reference: PMID:17826948
  title: "Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation."
  findings: []
- reference: PMID:28586844
  title: "Skeletal Muscle Involvement in Antisynthetase Syndrome."
  findings: []
- reference: PMID:35634293
  title: "Aminoacyl-tRNA Synthetases: On Anti-Synthetase Syndrome and Beyond."
  findings: []
- reference: PMID:38973731
  title: "2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases."
  findings: []
- reference: PMID:39083028
  title: "Management and outcomes of interstitial lung disease associated with anti-synthetase syndrome: a systematic literature review."
  findings: []
- reference: PMID:39467037
  title: "Clinical Characteristics of Anti-Synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome Project."
  findings: []
- reference: PMID:41376133
  title: "Clinical profiles associated with rapidly progressive interstitial lung disease in antisynthetase syndrome: A multicentric cohort study (TYPASS study)."
  findings: []
- reference: PMID:42121132
  title: "Disparate periphery and lung immune microenvironments induced monocyte-macrophage activation as a key factor in anti-synthetase syndrome-associated interstitial lung disease."
  findings: []
- reference: clinicaltrials:NCT01276470
  title: "Environmental Risk Factors for the Anti-Synthetase Syndrome"
  findings: []
- reference: clinicaltrials:NCT03770663
  title: "Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung Disease : Multicentric Randomized Phase III Trial"
  findings: []
datasets:
- accession: geo:GSE330891
  title: Spatial and cell type specific molecular genetic investigations of inflammatory myopathies with selective perifascicular injury.
  description: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of systemic autoimmune disease often with multisystem involvement. Targeted therapy is still lacking. Efficient serum or histological markers to measure disease activity and predict disease course are missing. Perifascicular myofiber atrophy is a hall mark of dermatomyositis (DM). Despite decades of research, the mechanism of perifascicular atrophy is still incompletely understood. Across other IIM subtypes, perifascicular myofiber necrosis is also the hall mark pathology for antisynthetase syndrome associated myositis (ASyS)5, and can be seen in a subset of lupus myositis (LM).
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: SPATIAL_TRANSCRIPTOMICS
  sample_count: 301
  publication: PMID:42427858
  notes: Identified by GEO DataSets index search for Antisynthetase Syndrome (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
📚

References & Deep Research

References

15
PMID:36280495
Mechanistic perspectives on anti-aminoacyl-tRNA synthetase syndrome.
No top-level findings curated for this source.
PMID:27594777
The Diagnosis and Treatment of Antisynthetase Syndrome.
No top-level findings curated for this source.
PMID:39814448
Epidemiology of Antisynthetase Syndrome and Risk of Malignancy in a Population-Based Cohort (1998-2019).
No top-level findings curated for this source.
PMID:22771754
Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity.
No top-level findings curated for this source.
PMID:28339994
A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies.
No top-level findings curated for this source.
PMID:17826948
Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation.
No top-level findings curated for this source.
PMID:28586844
Skeletal Muscle Involvement in Antisynthetase Syndrome.
No top-level findings curated for this source.
PMID:35634293
Aminoacyl-tRNA Synthetases: On Anti-Synthetase Syndrome and Beyond.
No top-level findings curated for this source.
PMID:38973731
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.
No top-level findings curated for this source.
PMID:39083028
Management and outcomes of interstitial lung disease associated with anti-synthetase syndrome: a systematic literature review.
No top-level findings curated for this source.
PMID:39467037
Clinical Characteristics of Anti-Synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome Project.
No top-level findings curated for this source.
PMID:41376133
Clinical profiles associated with rapidly progressive interstitial lung disease in antisynthetase syndrome: A multicentric cohort study (TYPASS study).
No top-level findings curated for this source.
PMID:42121132
Disparate periphery and lung immune microenvironments induced monocyte-macrophage activation as a key factor in anti-synthetase syndrome-associated interstitial lung disease.
No top-level findings curated for this source.
clinicaltrials:NCT01276470
Environmental Risk Factors for the Anti-Synthetase Syndrome
No top-level findings curated for this source.
clinicaltrials:NCT03770663
Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung Disease : Multicentric Randomized Phase III Trial
No top-level findings curated for this source.

Deep Research

1
Claude Code ▸
1. Disease Information
claude-haiku-4-5-20251001, claude-opus-4-8[1m] 11 citations 2026-06-29T19:55:12.157273

1. Disease Information

Overview. Antisynthetase syndrome (ASSD / ASyS / ASS) is a systemic autoimmune disease, a distinct subset of the idiopathic inflammatory myopathies (IIM), defined serologically by circulating autoantibodies directed against one of the cytoplasmic aminoacyl-tRNA synthetases (aaRS). It is clinically dominated by a triad of interstitial lung disease (ILD), inflammatory myositis, and inflammatory (usually non-erosive) arthritis, frequently accompanied by the "ancillary" features mechanic's hands, Raynaud phenomenon, and unexplained fever. ILD is the chief driver of morbidity and mortality and often predominates at presentation, so the disorder is genuinely a multisystem connective-tissue disease rather than "just a myopathy."

"Antisynthetase syndrome is characterized by symptoms of muscle weakness, arthritis, mechanic's hands, interstitial lung disease (ILD), Raynaud phenomenon, and a positive anti–tRNA-synthetase antibody." [search-derived]

Key identifiers: - MONDO: MONDO:0019344 — antisynthetase syndrome [verified via local OAK] - Orphanet: ORPHA:81 (Antisynthetase syndrome) - OMIM: No single Mendelian OMIM entry (complex/polygenic autoimmune disease — not a monogenic disorder) - ICD-10: No dedicated code; typically captured under M35.8 (other specified systemic involvement of connective tissue) or the myositis/ILD codes (e.g., M33.x dermatomyositis/polymyositis; J84.x for the ILD component) - ICD-11: 4A41 region (overlap/undifferentiated connective tissue diseases / inflammatory myopathies); no unique stem code - MeSH: No standalone MeSH descriptor; indexed via "Myositis," "Lung Diseases, Interstitial," and the supplementary concept for aminoacyl-tRNA synthetase autoantibodies

Data derivation: Disease-level aggregated resources (review syntheses, multicenter cohorts such as AENEAS, registry/population studies). A small amount is EHR/population-based (e.g., the Olmsted County population cohort, PMID 39814448).

Synonyms / alternative names: Anti-synthetase syndrome; anti-aminoacyl-tRNA synthetase syndrome; anti-ARS syndrome; ASyS; ASSD; Jo-1 syndrome (when anti-Jo-1 positive — a partial synonym); "antisynthetase syndrome–associated ILD (ASS-ILD)" for the pulmonary-predominant phenotype.

2. Etiology

Causal factors. ASSD is a multifactorial autoimmune disease — there is no single causal gene or pathogen. It arises from a loss of immune tolerance to one or more aaRS enzymes in a genetically susceptible host, likely triggered or amplified by environmental/mucosal (especially pulmonary) exposures. The serological hallmark — an anti-aaRS antibody whose titer tracks disease activity — implies the autoantibody response is mechanistically central rather than a bystander.

"titers of the serum anti-Jo-1 antibodies correlate with disease activity" — Kanaji et al., Trends Biochem Sci (PMID 36280495) [verified]

Genetic risk factors (susceptibility loci — not Mendelian causes): - MHC class II is the strongest risk locus. In Caucasian patients, HLA-DRB1*03:01 and the linked HLA-B*08:01, HLA-DQA1*05:01, and HLA-DQB1*02:01 alleles (the ancestral 8.1 haplotype) are the principal predisposing markers, particularly for anti-Jo-1. HLA-DRB1*07:01 appears protective. [search-derived] - In Korean/Japanese populations, anti-ARS associates with HLA-DRB1*08:03 (an example of population-specific HLA risk). [search-derived] - Non-HLA candidate: single-nucleotide variants in IL1B influencing IL-1β serum levels have been reported as susceptibility factors (PMC7732678). [search-derived]

Environmental / lifestyle risk factors: - Sex: female predominance (≈2–3:1 female:male). - Smoking: associated with increased risk of anti-Jo-1 positivity specifically in HLA-DRB1*03–positive individuals — a candidate gene–environment interaction. - Age: peak onset in the 5th–6th decades.

Gene–environment interaction (mechanistic hypothesis): the interaction between HLA-DRB1*03 and cigarette smoke is hypothesized to promote anti-Jo-1 generation — analogous to the smoking × shared-epitope model in rheumatoid arthritis, with the lung as the site of tolerance breakdown (post-translational modification/neoantigen exposure of HisRS in inflamed lung). [search-derived]

Protective factors: HLA-DRB1*07:01 (genetic, above). No well-established environmental protective factor.

3. Phenotypes

ASSD presents as "complete" (full triad) or, more commonly, "incomplete" forms; manifestations accrue over time, so the picture evolves. Approximate frequencies vary widely by cohort and by antibody (see §9). The figures below are pooled from the diagnosis/treatment review (PMID 27594777) [verified] and standard reviews.

Phenotype Type Approx. frequency Suggested HPO term
Interstitial lung disease (NSIP > OP > UIP patterns; dyspnea, dry cough) Clinical/imaging 70–90% (86% in one 203-pt cohort) HP:0006530 Abnormal pulmonary interstitial morphology
Inflammatory myositis / proximal muscle weakness Sign ~60–75% HP:0003701 Proximal muscle weakness; HP:0003198 Myopathy
Inflammatory arthritis / arthralgia (symmetric, non-erosive, often RA-mimicking) Sign ~50–60% HP:0001369 Arthritis; HP:0002829 Arthralgia
Mechanic's hands (hyperkeratotic, fissured, scaling skin of radial/ulnar fingers) Physical sign ~30% HP:0010765 Palmar hyperkeratosis (closest; "mechanic's hands" lacks a precise HPO term — verify)
Raynaud phenomenon Symptom ~40% HP:0030880 Abnormal vascular physiology / HP:0033740? → use HP:0030880-family; commonly mapped to Raynaud phenomenon — verify term
Fever (unexplained, often at flares) Symptom ~20% HP:0001945 Fever
Dyspnea Symptom common HP:0002094 Dyspnea
Elevated creatine kinase Lab abnormality common when myositis present HP:0003236 Elevated circulating creatine kinase concentration
Dysphagia (esophageal/pharyngeal muscle) Symptom subset HP:0002015 Dysphagia
Pulmonary fibrosis (late) Imaging/path subset, prognostic HP:0002206 Pulmonary fibrosis
Pulmonary arterial hypertension (late complication) Sign subset, poor prognosis HP:0002092 Pulmonary arterial hypertension
Myalgia Symptom common HP:0003326 Myalgia

Phenotype characteristics: Adult-onset (mean 43–60 yr; see §9). Onset is subacute-to-chronic and insidious; course is typically chronic, relapsing, and frequently progressive in the lung. Severity is highly variable — from clinically amyopathic/ILD-only (often non-Jo-1 antibodies) to fulminant myositis or rapidly progressive ILD. Mechanic's hands and Raynaud are markers of the syndrome but rarely disabling; ILD severity drives prognosis.

Quality-of-life impact: Dominated by the ILD (exertional dyspnea, oxygen dependence, reduced exercise capacity) and by myositis-related functional limitation (climbing, lifting, swallowing). Arthritis adds RA-like functional impairment. No ASSD-specific PRO instrument; SF-36/EQ-5D and myositis tools (e.g., HAQ, Myositis Activities Profile) are used generically.

4. Genetic / Molecular Information

This is not a Mendelian disease — there are no causal germline mutations. The "molecular genetics" are HLA susceptibility (see §2): HLA-DRB1*03:01, HLA-B*08:01, DQA1*05:01, DQB1*02:01 (8.1 haplotype) confer risk; DRB1*07:01 protective; DRB1*08:03 in East Asians. HGNC anchors for the relevant loci: HGNC:4948 HLA-DRB1, HGNC:4932 HLA-B, HGNC:4942 HLA-DQA1, HGNC:4944 HLA-DQB1; HGNC:5992 IL1B (candidate modifier).

Autoantigen genes (the targets of the autoantibodies, not mutated genes): the eight aaRS genes — HGNC:4815 HARS1 (HisRS / Jo-1), HGNC:11572 TARS1 (ThrRS / PL-7), HGNC:348 AARS1 (AlaRS / PL-12), HGNC:6053 IARS1 (IleRS / OJ), HGNC:4162 GARS1 (GlyRS / EJ), HGNC:751 NARS1 (AsnRS / KS), HGNC:3650 FARSB (PheRS / Zo), HGNC:6512 KARS1 (LysRS / SC/Ha).

No somatic variants, no chromosomal abnormalities, no established disease-specific epigenetic signature define ASSD. The molecular pathology is autoantibody- and immune-mediated, not genomic. Functional consequence of the autoimmunity is loss-of-tolerance and immune-complex formation (see §6), not loss/gain of aaRS enzymatic function.

Modifier serologies (act like molecular modifiers of phenotype): anti-Ro52/TRIM21 co-positivity (up to ~50% of patients) associates with more ILD and worse pulmonary outcome. HGNC:11312 TRIM21.

5. Environmental Information

  • Smoking — strongest candidate environmental factor; interacts with HLA-DRB1*03 to promote anti-Jo-1 (see §2). [search-derived]
  • Pulmonary exposures / mucosal injury — the lung is hypothesized as the initiating site where aaRS (HisRS) is secreted/modified and presented, breaking tolerance (consistent with ILD-predominant presentations). [verified mechanism, PMID 36280495]
  • Infectious agents: No specific pathogen is established as causal. Viral infection is a proposed nonspecific "danger signal" that upregulates aaRS secretion from infected macrophages (secretome studies show aaRS release from virus-infected macrophages, PMID 36280495 [verified]), but ASSD is not an infectious disease.
  • Occupational/toxin exposures: none specifically established.

6. Mechanism / Pathophysiology

The current model is a self-amplifying innate-plus-adaptive autoimmune loop centered on aaRS autoantigens, with the lung and muscle as the principal sites. Cited details are from Kanaji et al. (PMID 36280495) [verified] unless noted.

Causal chain (upstream → downstream):

  1. Tissue injury / regeneration + tissue-specific aaRS secretion (upstream trigger). Damaged or regenerating muscle (and inflamed lung) upregulate MHC class I on myofibers and secrete certain aaRSs. IGF-1–stimulated human skeletal muscle cells selectively secrete HisRS (not MetRS), and most ASSD-linked aaRSs appear in the secretome/exosomes of differentiating myoblasts and virus-infected macrophages — implicating extracellular mobility as a key determinant of which aaRS becomes an autoantigen (~85% of patients target a class IIa aaRS not bound in the multisynthetase complex).

    "most aaRSs detected from the secretome/exosome of human differentiating myoblasts and virus-infected primary macrophages are associated with ASSD."

  2. Neoepitope exposure — the WHEP domain. HisRS (Jo-1) is the dominant target (30–60%). The immunodominant epitope is the WHEP domain — a small (~50-aa) helix-turn-helix motif outside the catalytic core that is "highly exposed and flexible, often disordered." A lung-enriched HisRS splice variant (aa 1–60) and a granzyme-B cleavage fragment (HisRS1-48) expose this domain extracellularly, linking cytotoxic muscle/lung injury to autoantigen generation.

  3. Antigen presentation & T-cell help. Dendritic cells take up secreted aaRS and present peptides on MHC class II (HLA-DR) to aaRS-specific CD4+ T cells, driving B-cell help and class-switched autoantibody production.

  4. Immune-complex formation + TLR-driven interferon (the amplification loop). Anti-Jo-1 binds HisRS together with HisRS-bound tRNA/tRNA fragments, forming immune complexes. Via Fcγ receptors, complexes are internalized into endosomes where the nucleic-acid cargo triggers TLR7/8, releasing type I interferon and proinflammatory cytokines — a positive feedback loop that perpetuates autoantibody production. A 5′-half tRNA-His fragment released in extracellular vesicles can activate endosomal TLR7.

    "the HisRS/tRNA complex is internalized to the endosome, where the tRNA triggers TLR7/8 signaling and interferon release."

  5. Interferon programs (effector arm). ASSD muscle shows type II IFN–inducible genes (e.g., PSMB8) and MHC-II/HLA-DR upregulation on myofibers; type I IFN drives autoantibody persistence and MHC class I overexpression. In ASS-ILD, monocyte-driven IFN and TNF programs orchestrate the inflammatory network (Frontiers Immunol 2025, PMC12589074). [search-derived]

  6. Neutrophils / NETs (tissue-damage effector). Myositis-specific antibodies promote NET formation with impaired NET degradation, contributing to injury in lung, muscle, and vessels — a proposed driver of the fibrotic ILD (parallels RA-ILD NET biology). [search-derived]

  7. Chemokine activity of the autoantigen. The HisRS WHEP domain has intrinsic chemokine-like activity (activates chemokine receptors on T cells and immature dendritic cells), recruiting immune cells to tissues expressing/secreting it — a built-in feed-forward to sites like muscle and lung.

  8. Downstream tissue damage → clinical disease. The net result is interstitial lung inflammation/fibrosis, myofiber injury (perimysial/perifascicular, with MHC-I upregulation), synovitis, and vasculopathy (Raynaud, mechanic's hands).

Ontology suggestions: - GO (biological processes): GO:0002377 immunoglobulin production; GO:0019882 antigen processing and presentation; GO:0002224 toll-like receptor signaling pathway; GO:0032606 type I interferon production; GO:0032609 type II interferon production / GO:0034341 response to type II interferon; GO:0006954 inflammatory response; GO:0140447 cytokine production involved in inflammatory response; (NET formation: GO:0140148-family — verify a current NETosis GO ID); GO:0004812 aminoacyl-tRNA ligase activity (autoantigen's native function). - CL (cell types): CL:0000576 monocyte; CL:0000775 neutrophil; CL:0000451 dendritic cell; CL:0000624 CD4-positive T cell; CL:0000236 B cell; CL:0000786 plasma cell; CL:0002063 type II pneumocyte; CL:0000057 fibroblast; CL:0000187 muscle cell / CL:0000188 skeletal muscle cell. - GO cellular component (subcellular): GO:0005768 endosome (TLR signaling site); GO:0005737 cytoplasm (aaRS native compartment).

7. Anatomical Structures Affected

Organ level (primary): - Lung (UBERON:0002048) — interstitium; ILD is the dominant organ injury. Patterns: NSIP (most common), organizing pneumonia, UIP, sometimes diffuse alveolar damage. - Skeletal muscle (UBERON:0001134; muscle organ UBERON:0002385) — inflammatory myopathy, perimysial/perifascicular distribution. - Joints / synovium (UBERON:0002217 synovial joint; UBERON:0002484 synovial membrane) — inflammatory arthritis.

Secondary / additional involvement: - Skin (UBERON:0002097) — mechanic's hands; sometimes DM-like rash (Gottron, heliotrope) in overlap. - Peripheral vasculature / digital vessels — Raynaud phenomenon. - Esophagus (UBERON:0001043) — dysphagia from striated-muscle involvement. - Heart (UBERON:0000948) — under-recognized myocarditis and pulmonary hypertension/right-heart strain (late). [search-derived: anti-Jo-1 myocarditis reports]

Body systems: respiratory, musculoskeletal, integumentary, cardiovascular, immune.

Tissue/cell level: alveolar epithelium (type II pneumocytes), pulmonary interstitial fibroblasts/myofibroblasts; skeletal myofibers; synovial lining; recruited monocytes, neutrophils, T and B cells.

Localization / lateralization: ILD is bilateral, typically basal/peripheral predominant. Myositis is proximal and symmetric. Arthritis is symmetric/polyarticular. Mechanic's hands are bilateral on radial/ulnar finger surfaces.

8. Temporal Development

  • Onset: Adult, mean age 43–60 yr (range ~19–82); peak incidence 50–59 yr. Pattern is subacute-to-chronic/insidious; a minority present with rapidly progressive ILD (acute, potentially fatal).
  • Progression: Manifestations accumulate over time ("incomplete" → "complete" syndrome). The AENEAS time-course work shows new features (e.g., ILD, arthritis) emerging during follow-up. ILD course ranges from stable to relentlessly progressive fibrosis; ~32–35% progress despite steroids + immunosuppressant, requiring rescue therapy. [search-derived]
  • Disease course pattern: Chronic, relapsing-remitting to progressive; lifelong. Muscle and joint disease often respond to immunosuppression; ILD is the limiting factor.
  • Remission: Treatment-induced remission of myositis/arthritis is common; ILD often only stabilizes. Spontaneous remission is uncommon.
  • Critical windows: Early aggressive treatment of rapidly progressive ILD is the key intervention window; delayed diagnosis (common, due to under-recognition and incomplete presentations) worsens outcome.

9. Inheritance and Population

Epidemiology: - Incidence: age-/sex-adjusted ~0.56 per 100,000/year (95% CI 0.25–0.87) in a US population-based cohort (Olmsted County, 1998–2019; PMID 39814448). [search-derived] - Prevalence: rare; not precisely established. Orphanet lists it as a rare disease. - Sex ratio: female-predominant, ~2–3:1 (some myositis-predominant cohorts skew more female). - Age distribution: adult, peak 5th–6th decade.

Inheritance: Not inherited in a Mendelian fashion — multifactorial/polygenic with HLA-driven susceptibility. No penetrance/expressivity/anticipation/mosaicism/carrier-frequency concepts apply. Founder/population effects appear only at the level of population-specific HLA risk alleles (DRB1*03:01 in Europeans; DRB1*08:03 in East Asians). Consanguinity is not relevant.

Antibody distribution (defines serologic subgroups): - Anti-Jo-1 (HARS1): most common — ~20–30% of all IIM; ~70–88% of antisynthetase patients (72% in AENEAS, n=828). Phenotype: classic triad, more myositis. - Anti-PL-7 (TARS1): ~18% of anti-ARS (Japanese cohort). - Anti-PL-12 (AARS1): ~11%; ILD-predominant, often amyopathic, less muscle. - Anti-EJ (GARS1): ~23% (Japanese); myositis-associated. - Anti-OJ (IARS1): ~5%; ILD-predominant. - Anti-KS (NARS1): ~8%; ILD-predominant, minimal myositis. - Anti-Zo (FARSB) and anti-Ha/SC (KARS1): rare.

"Myositis was closely associated with anti-Jo-1, anti-EJ, and anti-PL-7, while interstitial lung disease (ILD) was correlated with all 6 anti-ARS antibodies." [search-derived]

Co-antibody: anti-Ro52/TRIM21 in up to ~50% — marks more severe ILD.

Geographic distribution: Worldwide; no strong endemicity. Subtype distribution shifts by ancestry (e.g., higher anti-EJ in Japanese cohorts).

10. Diagnostics

Diagnosis = anti-aaRS antibody + ≥1 compatible clinical feature (per Connors); Solomon criteria are stricter. Connors/Lega criteria are more sensitive; specificities are comparable. [verified PMID 27594777 + search-derived]

Serology (cornerstone): - Myositis line/immunoblot panels detecting the 8 anti-aaRS (anti-Jo-1, PL-7, PL-12, EJ, OJ, KS, Zo, Ha). Immunoprecipitation remains a reference method (best for anti-OJ, which line blots miss). Anti-Ro52 should be tested concurrently. - Caveat: patients can be antibody-positive yet "seronegative" by limited panels (anti-OJ, anti-KS frequently missed) — clinical suspicion matters.

Laboratory: - Creatine kinase (LOINC:2157-6) and aldolase — elevated with active myositis (may be normal in amyopathic/ILD-predominant disease). - ANA (often negative or low-titer cytoplasmic pattern — a clue), aldolase, LDH, AST/ALT.

Imaging: - HRCT chest — NSIP/OP/UIP patterns; the key ILD test. - Muscle MRI — edema/inflammation, guides biopsy.

Functional / electrophysiology: - Pulmonary function tests (PFTs) with DLCO — restrictive pattern, reduced diffusion; monitored every 2–3 months until remission. - EMG — irritable myopathy.

Biopsy / pathology: - Muscle biopsy — characteristic perimysial fragmentation, perifascicular necrosis, MHC-I sarcolemmal upregulation (distinct from DM's perifascicular atrophy and PM's endomysial pattern). - Lung biopsy — rarely needed; cellular/fibrotic NSIP, OP.

Genetic testing: Not used diagnostically (no Mendelian basis). HLA typing is research/risk-stratification only. WGS/WES/panels/karyotype/CMA/FISH/mtDNA/repeat testing are not applicable.

Omics-based diagnostics: Investigational — peripheral-blood IFN signatures, monocyte transcriptomics (ASS-ILD), and autoantibody profiling are research tools, not validated clinical diagnostics.

Clinical criteria: Connors (2010), Solomon (2011), Lega; ACR/EULAR IIM criteria capture the myositis component but not ILD-predominant ASSD.

Differential diagnosis: Other IIM (DM, PM, IMNM, IBM); idiopathic pulmonary fibrosis / idiopathic NSIP; rheumatoid arthritis (ASSD arthritis is RA-mimicking, can be anti-CCP–negative → "seronegative RA" reclassified as ASSD); systemic sclerosis/MCTD; hypersensitivity pneumonitis; Sjögren-ILD.

Screening: No population screening. In a patient with unexplained ILD, myositis antibody panel is the key targeted "screen."

11. Outcome / Prognosis

  • Mortality / survival: 10-year cumulative survival ~70% (anti-Jo-1) vs ~49% (non-Jo-1); one 5-year cohort (n=45) showed 14% mortality; AENEAS-era and registry cohorts report overall mortality ~25%. [verified PMID 27594777 + search-derived]
  • Leading causes of death: progressive pulmonary fibrosis and pulmonary hypertension; rapidly progressive ILD acutely.
  • Prognostic factors: Better — anti-Jo-1 positivity, presence of arthritis, presence of muscle weakness; Worse — severe baseline dyspnea, absent muscle weakness (ILD-only phenotype), non-Jo-1 antibodies, anti-Ro52 co-positivity, UIP-pattern fibrosis, PAH, older age.
  • Anti-Jo-1 antibody level tracks disease activity/evolution and is being evaluated as a longitudinal biomarker (PMC11137886, PMC10362709). [search-derived]
  • Malignancy: Cancer risk in ASSD is lower than in classic dermatomyositis but the population cohort (PMID 39814448) examined malignancy association — verify the specific hazard before citing.
  • Morbidity/QoL: chronic dyspnea, oxygen dependence, exercise limitation, myositis-related functional loss, RA-like joint disability.

12. Treatment

No randomized controlled trials exist — management is consensus/expert-based. (MAXO:0000058-family immunosuppressive therapy; NCIT:C15986 Pharmacotherapy as the action term.)

First line: - Glucocorticoids (prednisone/prednisolone), medium-to-high dose — CHEBI:8382 prednisone / CHEBI:8378 prednisolone; agent class NCIT:C2322 Corticosteroid. (MAXO:0000058? prefer NCIT:C15986 + corticosteroid agent.) - Steroid-sparing immunosuppressant added early — mycophenolate mofetil (CHEBI:8764), azathioprine (CHEBI:2948), or tacrolimus (CHEBI:61049) as add-on.

"prednisone AND mycophenolate mofetil or azathioprine; consider tacrolimus as add-on therapy" — PMID 27594777 [verified]

Refractory / progressive ILD: - Rituximab (anti-CD20 mAb; rescue therapy; PFT improvement at ~6 months) — agent NCIT:C2480 Rituximab; modality MONOCLONAL_ANTIBODY. - Cyclophosphamide (CHEBI:4026) for severe/rapidly progressive ILD or ARDS-like presentation. - IVIG — adjunct, especially for refractory myositis/dysphagia. - Combination MMF + rituximab reported beneficial in refractory IIM. [search-derived]

Antifibrotic (emerging): Nintedanib (CHEBI:85164) for progressive fibrosing ILD phenotypes (extrapolated from INBUILD/progressive-pulmonary-fibrosis data) — investigational/adjunct in ASS-ILD.

Targeted/experimental: JAK inhibitors (targeting the IFN axis) and other biologics are under study; numerous trials for myositis-ILD on ClinicalTrials.gov (search for active NCTs before listing).

Supportive / rehabilitative: supplemental oxygen, pulmonary rehabilitation, physical/occupational therapy (MAXO:0000011 physical therapy), aspiration precautions for dysphagia, vaccination/PJP prophylaxis under immunosuppression, lung transplantation for end-stage ILD (MAXO:0010039 organ transplantation).

Pharmacogenomics: TPMT/NUDT15 genotyping before azathioprine (myelosuppression risk) — standard CPIC guidance; the one genotype-guided step relevant to ASSD therapy.

Monitoring: PFTs/DLCO every 2–3 months until remission; CK and muscle strength for myositis; HRCT for ILD progression.

13. Prevention

  • Primary prevention: None established (autoimmune, multifactorial). Smoking cessation is the only modifiable lifestyle lever plausibly reducing risk (given the smoking × HLA-DRB1*03 interaction).
  • Secondary prevention (early detection): Early myositis-antibody testing in unexplained ILD/arthritis, and HRCT/PFT screening in newly diagnosed antibody-positive patients, to catch ILD before irreversible fibrosis. No population screening program.
  • Tertiary prevention: Immunosuppression to prevent ILD progression; infection prophylaxis (PJP, vaccination) while immunosuppressed; PAH surveillance; aspiration precautions.
  • Immunization, genetic screening/counseling, public-health/environmental interventions: Not applicable as disease-specific measures (no infectious or Mendelian basis); standard immunosuppression-related vaccination applies.

14. Other Species / Natural Disease

  • Taxonomy: Human disease — NCBITaxon:9606 (Homo sapiens).
  • Natural disease in other species: None recognized. ASSD has no described naturally occurring animal counterpart (no OMIA entry). It is defined by human anti-aaRS autoantibodies in a specific HLA context.
  • Orthologous autoantigen genes (for comparative/model work): the aaRS genes are deeply conserved (essential housekeeping enzymes) across all species — e.g., mouse Hars1 (NCBI Gene mouse ortholog), etc. — but conservation of the enzyme does not imply conservation of the disease.
  • Zoonotic potential / cross-species transmission: None (non-infectious autoimmune disease).

15. Model Organisms

ASSD is difficult to model; no single model recapitulates the full human triad.

  • Mouse immunization models: Immunization with HisRS / Jo-1 (and especially the WHEP/N-terminal fragment) in adjuvant induces muscle and lung inflammation (myositis + ILD-like pulmonary infiltrates) in mice — the principal experimental system supporting the autoantigen-driven model (referenced in PMID 36280495 mechanism work). Evidence source: MODEL_ORGANISM.
  • In vitro / cellular: Human skeletal myoblast and macrophage secretome/exosome studies (HisRS secretion on IGF-1 stimulation; aaRS release from virus-infected macrophages); TLR7/8 reporter assays with tRNA fragments; T-cell activation assays of the HisRS WHEP domain (chemokine activity / NRP2 binding). Evidence source: IN_VITRO. (PMID 36280495 [verified].)
  • Genetic models: No knockout/knock-in disease model (aaRS knockouts are embryonic-lethal — these are essential enzymes), so reverse-genetic disease modeling is intrinsically limited.
  • Recapitulation & limitations: Immunization models reproduce muscle + lung autoimmunity and the autoantibody response, supporting the antigen-specific hypothesis, but do not reproduce the chronic fibrotic ILD, arthritis, mechanic's hands, or the human HLA context — a clear HUMAN_MODEL_MISMATCH candidate for a knowledge-gap note (model autoimmunity ≠ human chronic fibrosing multisystem disease).
  • Applications: mechanism of tolerance breakdown, role of aaRS fragments/WHEP domain, TLR/IFN amplification loop, candidate-therapy testing.

Consolidated Ontology Term Suggestions (for YAML)

  • Disease: MONDO:0019344 antisynthetase syndrome.
  • HPO phenotypes: HP:0006530 (ILD), HP:0003701 (proximal weakness), HP:0003198 (myopathy), HP:0001369 (arthritis), HP:0002829 (arthralgia), HP:0010765 (palmar hyperkeratosis ≈ mechanic's hands — verify), Raynaud (verify term), HP:0001945 (fever), HP:0002094 (dyspnea), HP:0003236 (elevated CK), HP:0002015 (dysphagia), HP:0002206 (pulmonary fibrosis), HP:0002092 (PAH).
  • GO: GO:0002377, GO:0019882, GO:0002224, GO:0032606, GO:0034341, GO:0006954, GO:0004812.
  • CL: CL:0000576, CL:0000775, CL:0000451, CL:0000624, CL:0000236, CL:0000786, CL:0002063, CL:0000057, CL:0000188.
  • UBERON: UBERON:0002048 (lung), UBERON:0001134 (skeletal muscle tissue), UBERON:0002217 (synovial joint), UBERON:0002097 (skin), UBERON:0001043 (esophagus).
  • CHEBI (drugs): CHEBI:8382 prednisone, CHEBI:8764 mycophenolate mofetil, CHEBI:2948 azathioprine, CHEBI:61049 tacrolimus, CHEBI:4026 cyclophosphamide, CHEBI:85164 nintedanib.
  • MAXO/NCIT (treatments): NCIT:C15986 Pharmacotherapy (+ agents); MAXO:0000011 physical therapy; MAXO:0010039 organ transplantation; MAXO:0000950 supportive care.

Key References (PMIDs to fetch & verify before curation)

PMID / ID What it supports Status
36280495 — Kanaji et al., Trends Biochem Sci 2022/2023, "Mechanistic perspectives on anti-aminoacyl-tRNA synthetase syndrome" Full pathophysiology: aaRS autoantigens, WHEP domain, TLR7/8–IFN loop, secretome, chemokine activity [verified]
27594777 — "The Diagnosis and Treatment of Antisynthetase Syndrome" (PMC5006392) Criteria, frequencies, the 8 antibodies, prognosis/survival, treatment algorithm [verified]
39814448 — Epidemiology of ASS & malignancy, population-based cohort 1998–2019, J Rheumatol Incidence 0.56/100,000; malignancy risk search-derived
PMC11050089 / MDPI IJMS 2024 — Review of ASS-associated ILD ILD patterns, NETs, pathogenesis search-derived
PMC12589074 — Monocyte-driven IFN/TNF programs in ASS-ILD (Front Immunol 2025) Monocyte IFN signature search-derived
PMC11137886 / PMC10362709 — Anti-Jo-1 antibody levels & prognosis Antibody titer as activity biomarker search-derived
AENEAS cohort (Cavagna et al.; n=828) Antibody distribution (Jo-1 72%), clinical time course search-derived — locate PMID
Anti-Ro52 cohort (Clin Exp Rheumatol) Ro52 ~50%, worse ILD search-derived

Sources (URLs): - https://pmc.ncbi.nlm.nih.gov/articles/PMC9974581/ (mechanism review, PMID 36280495) - https://pmc.ncbi.nlm.nih.gov/articles/PMC5006392/ (diagnosis/treatment, PMID 27594777) - https://pmc.ncbi.nlm.nih.gov/articles/PMC9136399/ (aaRS: on anti-synthetase syndrome and beyond) - https://pmc.ncbi.nlm.nih.gov/articles/PMC11050089/ (ASS-ILD review) - https://pubmed.ncbi.nlm.nih.gov/39814448/ (population epidemiology) - https://pmc.ncbi.nlm.nih.gov/articles/PMC11137886/ (anti-Jo-1 levels & prognosis) - https://pmc.ncbi.nlm.nih.gov/articles/PMC6222225/ (HLA/genetics, Hungarian cohort) - https://pmc.ncbi.nlm.nih.gov/articles/PMC7732678/ (IL1B susceptibility) - https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1652999/full (monocyte IFN/TNF in ASS-ILD) - https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=81 (Orphanet ORPHA:81) - https://rarediseases.org/rare-diseases/antisynthetase-syndrome/ (NORD overview)

Curation handoff notes

A kb/disorders/Antisynthetase_Syndrome.yaml entry already exists on this branch (MONDO:0019344, with pathophysiology and phenotype scaffolding). This report is structured to fill it out — prioritize: (1) the verified mechanism chain from PMID 36280495 (autoantigen secretion → WHEP epitope → immune complex → TLR7/8 → IFN loop → tissue damage); (2) antibody-subtype phenotype heterogeneity (§9); (3) the ILD-centric prognosis/treatment (§§11–12). Before any snippet becomes an evidence: item, run just fetch-reference PMID:XXXX then confirm the quote is an exact substring of the cached abstract — especially for every claim I flagged [search-derived], and watch for the mechanic's-hands and Raynaud HPO terms, which need OAK verification (the ontology may lack precise matches).